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Chapter 1 
General introduction 

Introduction 
1.1. Prostatic disease 
Prostatic diseases are rather frequently occurring disorders in the male population. 
Prostatic adenoma -better known as benign prostatic hyperplasia (BPH)- is the most common 
benign neoplasm in men. Prostate cancer is the most commonly diagnosed malignancy in men 
and second leading cause of male cancer death in 'Western countries!. In The Netherlands, the 
morbidity and mortality caused by this tumor are exceeded only by those originating in lung 
cancer; in 1991, 4,343 incident cases and 2,108 deaths from cancer of the prostate were 
recorded in a male population of 7.5 million2 , The risk of developing prostate cancer increases 
dramatically with age, as does the oCcurrence of the proliferative disorder BPH', Indeed, men 
over the age of 65 that do not present with symptoms of prostate cancer during life very 
frequently are found to contain microscopic malignant lesions upon autopsy4. Many patients 
with prostatic cancer are diagnosed with disseminated disease, The majority of these 
disseminated prostatic carcinomas are androgen dependent and respond to hormonal 
manipulation, i.e" medical or surgical castration5 , The effectiveness of this therapy, however, 
is only temporary; after an initial response the tumor escapes from endocrine regulation to 
become insensitive to treatment based on the withdrawal or blockade of androgens. Such 
patients will eventually die of disseminated hormone-refractory prostate cancer. The etiology 
of prostate cancer is not clearly defined, it is thought to be multifactorial, involving genetic, 
hormonal, dietary and environmental causes. The mechanisms leading to progression of 
prostate tumors to autonomy are also largely unknown, Moreover, despite decades of 
experience with different treatment modalities, there are still controversies relating to patient 
selection criteria and choice of treatment', The recent development of different (medical) 
treatments for BPH has given rise to similar discussions concerning benign enlargement of the 
gland', 
1.2 Prostatic growth regulation 
A better understanding of the mechanisms which regulate prostatic growth in the 
normal and neoplastic prostate may facilitate the eventual clinical manipulation of aberrant 
prostatic expansion. Prostatic growth and expression of differentiated function have been 
shown to be regulated through endocrine factors, extracellular matrix components, autocrine 
factors, and paracrine factors, all of which may be interdependent to various degrees, 
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1.2.1. Endocrine dependency 
With respect to endocrine regulation, the dependence of stromal cells' and epithelial 
cells'·11 in the prostate on androgens for their growth and development is well documented12 • It 
is also known that in eunuchs and early castrates no (adult) prostate develops and no prostate 
cancer nor BPH is found later on in !ifes, The mechanisms of transition of prostate cancer to a 
hormone-unresponsive growth are not yet understood, Clonal selection and clonal overgrowth 
of hormone-insensitive cells has often been suggested to be the cause of autonomous growth, 
However, the basic events, either genetic or epigenetic, that induce cellular hormone 
independence remain to be identified, 
1.2.2. Extracellular matrix 
With regard to the extracellular matrix (ECM) there is considerable support for the 
concept that stmctural links between stroma and epithelium, fmmed by components of the 
extracellular matrix, mediate and transduce signals between both compartments, Such 
interactions may playa role in the control of prostatic growth and development13,lO, 
The importance of ECM in stromal-epithelial interactions was demonstrated by the 
finding that extracts of ECM (from stromal cell cultures) can induce similar effects on 
epithelial cell behavior as intact stromal cells. Stromal tissues contain different types of 
macromolecules, including collagens, glycoproteins and proteoglycans. These molecules form 
extracellular matrix structures that contribute to tissue architecture by providing cell attachment 
sites. Adhesive interactions between cells and ECM stmctures playa cmcial role in epithelial 
morphogenesis!~, There is convincing evidence that ECM proteins also control differentiation 
and gene expression in adult organs 1S-17 , Transmembrane receptors, for instance belonging to 
the family of integrins!8, are assumed to mediate the transm.ission of external signals to the 
inside of the cell upon binding to ECM molecules. 
The recent observation that basic fibroblast growth factor (bFGF) binds with strong 
affinity to components of the extracellular matrix such as heparan sulfate proteoglycans and 
glycosaminoglycans, and that these bound forms of the bFGF can be mobilized in a stable 
fon11 by proteolytic cleavage of the extracellular matrix I9,20, suggests another mechanism 
whereby the extracellular matrix may regulate prostatic growth and development. 
1.2.3. Autocrine growth modulating factors 
Autocrine regulation of prostatic growth appears to involve a variety of growth factor 
polypeptides21 In this context, epidermal growth factor (EGF)-like and bFGF-like molecules 
account for a considerable amount of the growth factor activity in the prostate21 , In addition, 
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acidic PGP", transforming growth factor-beta (TGP-Jl)", and nerve growth factor (NGP)" 
have been identified in the prostate or prostatic tumor cell lines, Some of these growth factors 
may have a paracrine role as well. 
1.2.4. Paracrine regulatory factors 
Paracrine regulation of prostatic growth was first suggested by Pranks ef al,25 after 
observing a lack of growth capacity of epithelia which had been separated from their stroma, 
Subsequently, Cunha ef ai, demonstrated that fetal mesenchyme (stroma) induced prostatic 
epithelial morphogenesis from urothelium12 , The total prostatic growth correlated well with the 
amount of mesenchyme used26 . Under normal conditions epithelial cells continue to express 
their characteristic morphological and functional properties also during adulthood, This 
stability of epithelial differentiation appeared to be based on instl1lctive induction by the stroma 
rather than on irreversible commitment of the epithelial cells. Indeed, the proliferation of 
epithelial cells within the prostatic acini exhibits a regional heterogeneity, indicating that local 
control mechanisms, such as paracrine interactions with stroma, regulate differentiation and 
development27,28, However, even though several growth factors have been identified in the 
prostate from whole tissue homogenates and various cell lines, the specific growth factor 
interactions between epithelial cells and stromal cells, and therefore their identity as paracrine 
growth factors, remain to be investigated. 
1.3. Prostatic size 
1.3.1. Trophic inflnence of stroma 
Upon maturation, accessory sexual organs reach a typical size and weight which is 
characteristic for that particular organ, Administration of hyperphysiological doses of androgen 
to intact male rats did not stimulate prostatic growth beyond normal adult size. Likewise, 
administration of testosterone to androgen-deprived rats restores the size of the prostate to its 
normal precastration level without inducing overgrowth, even after prolonged administration12 . 
At that stage, epithelial cell proliferation is low and in balance with cell death', Experiments 
performed by Chung and Cunha" showed that epithelial cell growth and, therefore, absolute 
prostatic size was regulated by the amount of mesenchymal (stromal) tissue present. During 
embryological development, androgen receptors are present only in the mesenchyme, 
suggesting that at this stage all androgen-induced events are mediated via the stroma12 ·29 . 
Furthermore, it was shown that also in the adult rat prostate, the proliferative response to 
13 
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androgens was mediated through the stroma3D. 
Likewise, the in vitro growth of prostate epithelial cells was found to be stimulated by 
androgens in coculhlres with prostate stromal cells30,31, but not in isolated epithelial 
cultures"·J3. Interestingly, prostate stromal cells were shown to express keratinocyte growth 
factor (KGF) in response to androgens while epithelial cells expressed the gene coding for a 
receptor which specifically binds KGFJI. These observations strongly suggest that KGF is 
involved in the paracrine mechanism of androgen-regulated prostate epithelial growth. 
1.3.2. Negative control via the stroma 
At this point it is tempting to speculate about a regulatory role of the stroma also in 
castration-induced involution of the gland. Androgen-induced stromally derived inhibitors of 
epithelial cell growth could participate in keeping the delicate balance between cell 
proliferation and (programmed) cell death. Normal (non-transformed) murine and human 
prostatic epithelial cells grown in vitro were shown to proliferate in serum-free medium 
without the presence of androgens32 ,34-36. Androgen ablation in vivo (in the presence of 
connective tissue), however, induces a marked regression of the glandular epithelium9. These 
findings may be indicative of a role for the stroma in the negative control of epithelial cell 
proliferation. One of the well known inhibitors of epithelial cell growth, transforming growth 
factor-B (TGF-B), was shown to be present in prostate tissue". Its expression appeared to be 
regulated by androgens in an inversely related manne2g. However, both epithelial and stromal 
cells were found to be capable of expressing and secreting TGF-B in vitro, and there is still 
doubt about the actual site of TGF-B production in prostatic tissue. 
1.4. Scope of the thesis 
The aim of the present work was to study the stromal-epithelial interactions in the 
human prostate with special attention to exploring the hypothesis of a negative control of 
epithelial cell proliferation by prostatic stroma. 
Chapter 2 of this thesis sunmlarizes the available evidence demonstrating the profound 
influence of stroma on the epithelium. 
Since the majority of the experiments published were performed ;'l vivo using tissue 
recombinants such studies did not provide information about the exact nature of signal 
transducers between the two compartments as was mentioned in paragraph 1.2.4. For this 
reason we used an approach in which epithelial cells and stromal cells were physically 
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separated. To this end, human stromal cells were cultured from diseased prostates by means of 
tissue explant cultures; this method as well as the immunocytochemical characterization of 
such cells is described in chapter 3. 
Using a double layer soft agar system separating stromal and epithelial cells, a negative 
control of epithelial cell proliferation by prostatic stromal cells was found, as presented in 
chapter 4. 
Later it was shown that the epithelial cells were not only inhibited in their clonal 
growth (in soft agar), but also in their anchorage-dependent growth (on culture plastics). 
Furthermore, the anti-proliferative activity was found to be present in the conditioned medium 
of the stromal cells. This enabled us to employ a more simple bioassay, the MTT-test, making 
it possible to test a larger number of samples at the same time and to manipulate the 
conditioned medium before testing its activity on the prostatic epithelial cells. As is described 
in chapter 5, the results from such tests suggested that the antiproliferative activity was 
specifically produced by prostatic stromal cells and that the reversible inhibition of (prostatic) 
epithelial cell growth was organ but not species specific. 
The data presented in chapter 6 demonstrate that human prostate derived stromal cells 
cultured from neoplastic lesions produce a unique factor, tentatively called "prostate-derived 
epithelium inhibiting factor": p-EIF, which on the basis of its spectl1lm of biological activity as 
well as its physicochemical and immunoreactive properties, can be discriminated from 
previously described growth inhibitors. 
Finally, in chapter 7 the importance of these findings as well as possible directions of 
future research are discussed. 
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Chapter 2 

Stromal-epithelial interactions ill the prostate 
2.1. Introduction 
Since 1953. when Grobstein' published his study on the role of tissue interactions in 
the embryogenesis of the kidney, stronial-epithelial interactions have been shown to play a 
vital role in numerous organ functions. In a classic series of experiments on tissue 
recombinants, Cunha, Chung, and others have clearly demonstrated the importance of the 
embryonic mesenchyme in prostatic ductal morphogenesis, epithelial growth, secretory 
cytodifferentiation and function2-7 • By the use of tissues derived from mice with the testicular 
feminization syndrome (containing non-functional androgen receptors) they were able to show 
that probably all androgen-induced events during fetal life are mediated by mesenchyme. 
Tissue recombinants could be grown to maturity and striking similarities with the 
nOlmal adult prostate were observed, especially during castration-induced atrophy as well as 
androgen-induced regeneration of the gland. These findings suggest that these models are 
applicable to the adult prostate too. Moreover, in systems containing undifferentiated stem cell 
populations, an orderly process of epithelial differentiation and functional maturation must be 
maintained as cells continually die and have to be replaced'. Thus, fundamentally similar 
processes seem to occur in both the embryo and the adult. 
We have to evaluate these findings carefully to see whether they can provide us with 
any insight in the processes leading to neoplasia. This review will focus on those studies that 
show the importance of mesenchyme in the development of the gland as the mediator of 
androgenic effects upon the epithelium, and of the stroma in the homeostasis in the adult 
prostate. Further, studies on the stroma of neoplastic lesions are summarized and the leading 
theories about the etiology of benign prostatic hyperplasia (BPH) and prostatic cancer based on 
these observations are discussed. Special attention is paid to the action of androgens in the 
stromal-epithelial relationship in order to start unravelling the mechanisms that lead to 
hormone independent disease. 
2.2. Mesenchymal regulation of epithelial morphogenesis in the male genital 
tract 
The male genital tract develops from tlVO embryonic stmctures: the Wolffian duct and 
the urogenital sinus. The epithelium of the Wolffian duct is of mesodelmal origin and gives 
rise to the epididymis, ductus deferens, seminal vesicles and ejaculatory ducts. The urogenital 
sinus, of which the epithelium is endodelmal in origin, gives rise to the prostate, bulbourethral 
glands, urethra, periurethral glands and contributes to the urinary bladder"'. By analyzing the 
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development of heterotypic tissue recombinants, Cunha lO showed that urogenital sinus 
mesenchyme cannot induce seminal vesicle epithelium to express prostatic differentiation, but 
it is able to support the expression of the characteristics of seminal vesicle development 
(Figure la), Similarly (Figure Ib), seminal vesicle mesenchyme permits the normal expression 
of prostatic differentiation in epithelium of the urogenital sinus, and does not elicit seminal 
vesicle development from urogenital sinus epithelium. Therefore, in these permissive 
inductions (as opposed to instructive inductions), the heterotypic mesenchyme promotes 
expression of the normal developmental fate of the epithelium, Epithelia of mesodermal origin 
may only be able to differentiate into mesodermal derivatives, whereas endodermal epithelia 
may only be able to form endodermal derivatives', These findings were supported by analysis 
of tissue recombinants of bladder epithelium and mesenchyme from urogenital sinus9. 
Epithelium of the urinary bladder is endodermal in origin and in these experiments 
recombinants of urogenital sinus mesenchyme and bladder epithelium developed into prostate-
like structures (Figure Ic), Prostatic differentiation could be induced whether the bladder 
epithelium is derived from either fetal or adult animals", This represents an example of 
instructive induction because the mesenchyme reprograms the developmental fate of the 
epithelium3 . 
In a series of similar experiments, prostatic ductal morphogenesis was induced by 
combining urogenital sinus mesenchyme and epithelium derived from urogenital sinus, fetal or 
adult bladder, postnatal vagina or adult prostate"IO,12.1', All these epithelia are derived from the 
primitive endodennal urogenital sinus, It should be noted that these results can only be 
obtained if the recombinant is grafted into an intact male host (where androgen levels are 
adequate) and if urogenital sinus mesenchyme is used. Extensive analysis of urogenital sinus 
mesenchyme and adult bladder epithelium tissue recombinants demonstrated that the epithelial 
ducts induced by urogenital sinus mesenchyme express histological, ultrastructural and 
functional features typical for prostate tissue, including androgen receptors, prostate-specific 
antigens, androgen- dependent DNA synthesis, characteristic protein patterns and histochemical 
profiles indicative of the prostatic phenotype9,11,IS,16. 
Both instructive and permissive inductions by urogenital sinus mesenchyme appear to 
be mediated by similar, if not identical, signals in a variety of mammalian species, All 
heterospecific recombinants of urogenital sinus mesenchyme and urogenital sinus epithelium or 
bladder epithelium derived from mouse, rat, rabbit and human showed prostatic 
differentiation17 , From these experiments it is evident that the mediators of these inductive 
interactions are highly conserved in different mammalian species. 
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Figure 1 Schematic representation of the experiments on recombinants constructed with embryonic 
mesenchyme (from reference 3, with permission), 
2.3. Mesenchyme as a mediator of androgenic effects upon the epithelium 
The development of the prostate as well as the regulation of its adult stmcture and 
function are dependent on androgens. These processes are thought to be mediated by androgen 
receptors. Study on the testicular feminization syndrome (Tfm) provides strong support for the 
essential role of androgen receptors in prostatic development. Despite adequate testosterone 
levels, prostatic tissue never develops because of a non-functional androgen receptoil,ll, 
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Now that the importance of androgens and its receptor has been shown, the question 
remains whether intraepithelial receptors play any role in this process, for the administration of 
androgens to castrated mice elicits growth of the prostatic epithelium. Although in the adult 
mouse androgen receptors are present in both epithelium and stroma the fortuitous association 
of androgen-induced epithelial growth with intraepithelial androgen receptors, does not in and 
of itself prove that androgen-induced prostatic epithelial growth is mediated via androgen 
receptors within the epithelial cells themselves". Indeed, analysis of androgenic effects in 
Tfmlwild-type tissue recombinants provides strong evidence for the importance of 
mesenchymal, rather than epithelial, androgen receptors in prostatic development. 
First, Kratochwil and coworkers established the idea that mammary mesenchyme is the 
actual target and mediator of androgenic effects upon the developing mammary gland whose 
epithelial component regresses in response to testosterone 19 • Later on, the relevance of this 
concept to the prostate was confirmed by similar experiments in which mesenchyme and 
epithelium from urogenital sinuses of Tfrn and wild-type mouse embryos were combined ),10,11. 
The four possible types of tissue recombinants are indicated in Figure 2. All recombinants 
were exposed to physiological levels of androgens as they were implanted into intact male 
hosts. Prostatic morphogenesis occurred only in those recombinants constmcted with wild-type 
mesenchyme. The genotype of the epithelium was irrelevant, as both Wild-type and Tfm 
epithelia formed prostate in association with wild-type urogenital sinus mesenchyme. In 
contrast, prostatic differentiation did not occur in combinants constructed with Tfm 
mesenchyme even when wild-type epithelium was used. Thus, in the developing prostate and 
embryonic mouse manmlary gland, the mesenchyme is the actual target and mediator of 
androgenic effects upon the epithelium, whereas the genotype of the epithelial element does not 
influence the developmental response, This concept is supported by the observation of nuclear 
['Hjdihydrotestosterone (DHT) binding sites in mesenchymal cells of wild-type urogenital sinus 
and mammary gland using steroid autoradiography2o,21. Tfm urogenital sinus mesenchyme lacks 
nuclear ['HjDHT binding sites!'. Surprisingly, the epithelial cells of the developing wild-type 
glands appear to be devoid of androgen receptors too. The only obvious difference in androgen 
receptor content between wild-type and Tfm urogenital sinus and mammary gland was 
observed in the mesenchyme: receptors were present in mesenchymal cells of wild-type 
embryos but were completely absent in Tfm embryos!'. All the processes necessary for full 
prostatic development, i.e. ductal morphogenesis, epithelial proliferation and secretory 
cytodifferentiation, are expressed in the Tfm epithelium, which, in contrast to wild-type 
bladder epithelium22 , remains androgen receptor-negative even after prostatic induction23 . This 
indicates that all these androgen-induced events must be regulated by the receptor positive 
stromal cells. 
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feminization syndrome [non functional androgen receptor]; +: normal androgen receptor. 
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2.4. Stromal-epithelial interactions in adult organs 
For all organs, epithelial morphology and functional activity must be maintained as 
cells continually undergo senescence, die and are replaced. In these systems, cellular 
proliferation must be regulated in order to maintain normal stlUcture and function. Moreover, 
in systems containing undifferentiated stem cell populations, an orderly process of epithelial 
differentiation and functional maturation must be maintained8. Thus, fundamentally similar 
processes occur in both the embryo and the adult. In addition, for certain organ systems such 
as the female genital tract and the mammary gland, true morphogenetic processes occur in a 
cyclic fashion during menstrual CYCles, pregnancy and lactation. These events closely resemble 
the primary developmental events that occur in the prostate during the perinatal period'. 
Prostatic growth is stimulated by androgens while castration of adult males reduces 
prostatic DNA content to about 20% of the pre-castration level'·24. During this process about 
35 % of the ductal tips and branch points of the prostate completely degenerate from the distal 
(subcapsular) portion of the gland, while in proximal regions the epithelium merely undergoes 
simple atrophy, the ductal structures being maintained morphologically". Administration of 
testosterone elicits a marked increase in DNA synthesis in both epithelial and stromal cells, 
primarily in the distal tips of the atrophied prostatic ducts"'''. This ultimately leads to 
complete regeneration of the previously lost distal architecture and restoration of the prostate 
to its normal size, weight and functional activity24.25. Androgens elicit these effects by acting 
primarily on the stromal cells which in turn induce epithelial proliferation and maturation. This 
conclusion is based on the experiments described in the previous section and is supported by 
another series on tissue recombinants28,29, In these experiments, tissue recombinants composed 
of wild-type urogenital sinus mesenchyme and Tfm bladder epithelium have been grown to 
maturity and compared with wild-type prostate or tissue recombinants of wild-type urogenital 
sinus mesenchyme and wild-type bladder epithelium, Both combinations gave rise to prostate 
tissues of which the cells expressed androgen receptors I6,22. During this maturation the induced 
prostatic ducts became lined by differentiated secretory epithelial cells. The embryonic 
mesenchyme used to construct the recombinants differentiated into mature prostatic fibroblasts 
and smooth muscle cells. Adult rodent bladder epithelium also was shown to undergo prostatic 
differentiation including the appearance of androgen receptors, making this model relevant to 
mature prostatic epithelial and stromal cells. Two dimensional electrophoresis of the proteins 
produced by the recombinants of wild-type urogenital sinus mesenchyme and Tfm bladder 
epithelium and wild~type prostate showed striking similarities, although some minor 
differences were seenI4,28.29, Moreover, prostatic epithelial cells of the recombinants containing 
wild-type urogenital sinus mesenchyme and Tfm bladder epithelium or wild-type bladder 
26 
Stromal-epithelial interactions ill the prostate 
epithelium underwent similar histological changes during regression in response to androgen 
deprivation. Androgen-induced DNA synthesis, as assessed by biochemical and 
autoradiographic procedures, was comparable in prostates that were either completely wild-
type or were composed of wild-type urogenital sinus mesenchyme and Tfm bladder epithelium. 
This proliferation could be blocked by the anti-androgen cyproterone acetate. From these data 
it is evident that certain androgen effects (ductal morphogenesis, epithelial growth and 
secretory cyto-differentiation ) do not reqnire the presence of intraepithelial androgen 
receptors". So, several lines of evidence support the concept that in the adult prostate a 
multitude of epithelial features are regulated by androgens indirectly through androgen-
dependent mediators of stromal origin. 
The susceptibility of genuine adult prostatic epithelium to these embryonic inductors 
was shown by Chung and associates30• They implanted urogenital sinus mesenchyme or whole 
urogenital sinus in one lobe of the adult mouse ventral prostate and evaluated the growth (wet 
weight and DNA content) after different periods. As a result, after several months, massive 
growth was observed in the implanted lobe but not in the unimplanted, contralateral lobe. In 
these experiments they found that whole urogenital sinus induced 2.5-fold more growth than 
urogenital sinus mesenchyme while urogenital sinus epithelium was completely inactive. They 
explained this phenomenon by the possible modulation by urogenital sinus epithelium of the 
urogenital sinus mesenchyme gene expression that is responsible for inducing the proliferation 
of adult prostatic cells ( reciprocal mechanism ). However, since the urogenital sinus is the 
fetal counterpart of the adult prostate, given enough time and proper conditions, it will develop 
into an entire prostate gland. Indeed, Thompson and Chung showed that urogenital sinus, in 
contrast to urogenital sinus mesenchyme, grows to a considerable mass when inoculated under 
the renal capsule3J • Therefore it was still unclear whether the massive overgrowth observed in 
the urogenital sinus-implanted ventral lobes was due to the stimulation of the adult prostate or 
to the normal growth and development of the implanted urogenital sinus. To answer this 
question, Chung and coworkers examined glucose phosphate isomerase isoenzyme patterns and 
found equal levels of donor and recipient tissue isomers, suggesting equal contributions by 
both tissues toward the new growth observed. Scatchard analysis of cytosolic androgen 
receptors, however, revealed a pattern resembling that of the host prostateJ2 • Although these 
methods were described as a new mouse model for BPH, the question to what extent the 
enhanced effect was due to an increase in fetal urogenital sinus growth rather than to the 
growth of the host's ventral prostate could not be answered. Nevertheless, the growth caused 
by the urogenital sinus mesenchyme implants clearly demonstrated the capacity of mesenchyme 
to induce epithelial proliferation and differentiation in the adult prostate. 
Further evidence for the importance of stroma in prostatic growth was provided from 
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studies that examined the factors which regulate prostatic size, For any accessory sexual organ, 
a typical size and weight can be determined which is characteristic of the mature organ", 
Likewise, after a period of androgen deprivation, administration of testosterone restores the 
(rodent) prostate to its normal precastration size and no overgrowth is induced even after 
prolonged administration, Indeed, in intact adullS androgen levels are high while prostatic 
epithelial cell proliferation is low and in balance with cell death3J , To discern whether the 
regulation of prostatic growth is intrinsic or extrinsic, Chung and Cunha prepared homotypic 
recombinants with urogenital sinus mesenchyme and urogenital sinus epithelium in which the 
ratio of epithelium to mesenchyme was varied", Their results strongly suggested that epithelial 
growth and, therefore, absolute prostatic size were regulated by the amount of mesenchymal 
(stromal) tissue present. From this perspective we have to evaluate the observations made on 
intact adult prostates and those after castration as reported by DeKlerk and Coffey", They 
showed that in the intact male rat prostate the ratio of epithelial cells to stromal cells was 
3,3: I, while after castration a disproportionate loss of epithelial versus stromal cells occurred 
resulting in an epithelial-stromal ratio 1:2. As mentioned above, Sugimura and associates 
reported that during prostatic regression the epithelial cells of the ductal tips completely 
degenerate and the stromal tissue, which could not be discerned in whole-mount preparations 
before regression, became visible25 ,26. This last observation raised the distinct possibility that 
the relative loss of epithelial compared to that of stromal cells after castration may be different 
in different regions of the gland", This could, in turn, account for the heterogeneity of 
proliferative activity observed after androgen suppletion26,21. Furthermore, during prostatic 
development, a similar situation exists favoring the amount of stroma versus epithelium 
(prostatic buds), Since growth of the prostatic rudiment to the adult size is associated with a 
marked shift in the epithelial:stromal ratio, it may be that growth responsiveness of the adult 
prostate after androgen replacement therapy requires that the epithelial:stromal ratio favors the 
stromal element before growth can be induced, This would explain the inability of the prostate 
to be stimulated to grow beyond its normal size by exogenous sex steroids and the requirement 
of 4-7 days of androgen deprivation before DNA synthesis can be stimulated, This concept was 
tested by means of tissue recombinants prepared of a single epithelial ductal tip from adult 
prostate with mesenchyme from either the embryonic urogenital sinus or adult urinary 
bladderl4. Recombinants were transplanted under the renal capsule and grown for one month in 
the intact male mouse, Individual ducts were maintained but did not grow by themselves or 
when combined with bladder mesenchyme or Tfm urogenital sinus mesenchyme. However, 
when combined with (wild-type) urogenital sinus mesenchyme, massive prostatic ductal growth 
was achieved, such that a single 300 I'm ductal tip containing an extremely small number of 
epithelial cells gave rise to as much as 35 mg wet weight of prostatic tissue"''', These ducts 
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were derived from intact donors and, therefore, the ducts did not require prior castration-
induced atrophy or cell loss as a condition for growth response. Through analysis of similar 
recombinants with varying amounts of urogenital sinus mesenchyme, Neubauer and coworkers 
showed that new prostatic ductal tissue is formed in proportion to the amount of urogenital 
sinus mesenchyme used36 . 
It has to be emphasized that the above-mentioned experiments were all carried out with 
fetal stromal tissue. Unfortunately, comparable experiments utilizing adult prostatic stroma 
have not as yet been performed due to difficulties in isolating prostatic epithelium and stroma 
in adults. Those experiments that were carried out with adult stromal cells did show either 
marginally inductive activity or complete absence of inductive activity when implanted in the 
rat's ventral prostate". This inability could be due to the fact that these cells had to be cultured 
ill v;,ro before they were used. However, in the mammary gland, stroma from both the fetus 
and adult are interchangeable in that they both induce the growth and branching morphogenesis 
of fetal or adult mammary epitheliums.31 . 
In conclusion, it can be stated that short-range interactions between epithelium and 
stroma, which are of fundamental importance during morphogenesis in the embryo, are clearly 
involved in organ homeostasis in adulthood. For this reason, the development of cancer and 
other disease states is likely to involve a loss of coordination and alteration in the interactions 
between epithelial and stromal cells". 
Several investigators have been searching for the molecular bases of this homeostatic 
constraint mechanism that curtails further increase in cell number once the prostate has reached 
its normal size. Different possible inhibitory mechanisms have been discussed by Bmchovsky 
and associates some years ag039 and they considered the production of chalones40 by the 
prostatic epithelial cell as an attractive possibility to explain the negative feedback on 
proliferative growth of the prostate. Experiments carried out by Mtintzing and coworkers failed 
to show such an inhibitory effect'!. They implanted atrophied ventral prostates from 
orchiectomized rats into the ventral prostate of other rats. Under the influence of endogenous 
or exogenous androgen the DNA content of the ventral prostates was increased above normal, 
probably due to the inductive properties of the stroma as discussed before. Studying the rat 
ventral prostate, Kyprianou and Isaacs more recently showed an 40-fold increase of TGF-B 
mRNAs (a potent growth inhibitor of prostatic epithelial cells "), four days after castration. 
Androgen administration to four-day castrated rats led to a marked decrease in TGF-B mRNA, 
to a level comparable to its constitutive expression obtained in intact control animals, showing 
that expression of TGF-J3 is under negative androgenic regulation 43. In vitro and ill vivo 
experiments showed TGF-B to induce programmed cell death of rat ventral prostate glandular 
cells 44. Since these studies were performed on whole tissue homogenates, no conclusions 
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regarding the source of TGF-B can be drawn from these experiments. Kabalin and colleagues 
focused their attention on the stroma and found a stimulatory response of the epithelial cells in 
coculture with prostatic fibroblasts using a semm-free clonal growth assay45. However, at 
higher cell densities they observed an inhibition of cell growth. Several other investigators 
have studied the stromal-epithelial interaction in the prostate ill vitro, but their reports were 
mainly focused on the mitogenic influence of the stroma; all were using semm-free assays46-49. 
2.5. Role of epithelial-stromal interactions in prostatic disease 
2.5.1. Benign prostatic hyperplasia 
Benign prostatic hyperplasia can be viewed as a new organ developing from the 
internal or periurethral portions of the prostatic gland between the bladder neck and the 
vemmontanum as well as the adjacent transition zone50 , McNeal identified two cell types and 
sites of origin for small lesions less than 3 nun51 , First, those found in the periurethral smooth 
muscle were purely stromal in character or showed only a few small glands penetrating from 
the periphery. He noticed that the stroma was distinctively reminiscent of embryonic 
mesenchyme, with an abundance of pale ground substance and only a few collagen fibers. 
Secondly, lesions found in the transition zone were of epithelial origin. Characteristic features 
of glandular nodules were the abrupt increase in closeness of acinar packing and hypertrophy 
of individual epithelial cells. Furthermore, ducts adjacent to the nodule were found to send out 
branches exclusively on the nodule site growing into the nodular mass, but no branches were 
found on the opposite wall. These small lesions can be found occasionally in men in their 
fourth decade. Their number increases linearly with age, while the subsequent growth of each 
newly formed nodule is generally slow. Around the seventh decade there is a second phase of 
evolution, characterized by a rather abmpt and marked increase in the number of prostates 
having nodules of large mass. This latter increase in size is distinctively caused by glandular 
expansion and consequently in most men is limited to the transition zone. Nevertheless, in the 
fully developed state, the ratio of muscle tissue or fibromuscular stroma to epithelium is 
significantly greater than in the normal giand52 . 
As far as the etiology of BPH is concerned, a primary endocrine imbalance is not 
admissible, for the eady lesions are observed during a period in life in which no abnormalities 
in sex steroid levels are apparent be observed. Furthermore, nodule genesis, by definition, is 
sharply focal while an endocrine aberration would probably be expressed diffusely, at least 
tluoughout a given region. These observations have lead to the hypothesis that the initial 
abnormality in nodule genesis is a spontaneous reversion of a clone of stromal cells to the 
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embryonic state and that growth regulation in BPH may be under stromal regulation, as 
proposed by McNeal". Moreover, the putative embryonic (diffusible) mediators could be 
responsible for the observed eccentric growth of epithelial ducts at the border of a nodule 
towards its center, 
Indeed, from data presented in previous sections it is clear that (fetal) stroma is capable 
of inducing epithelial hyperplasia in adult prostates. Thus, an apparent similarity and 
parallelism can be shown between BPH stroma and embryonic mesenchyme in that both tissues 
express inductive activities that elicit morphogenesis and growth of prostatic epithelium, 
This concept does not rule out the possibility that hormones play a role in 
pathogenesis. The observation that BPH does not develop in men castrated prior to puberty"'" 
indicates that testicular factors are involved in the etiology of BPH. Furthermore, androgens 
are needed for the activation of the embryonic developmental program of the prostate and are 
necessary for the expression of reawakened embryonic capacities in adults. Interesting in this 
context is the observation made by Schweikert and associates that BPH fibroblasts metabolized 
testosterone to a much higher extent than fibroblasts grown from prostatic carcinoma, foreskin 
and non-genital skin". This was caused by the higher levels of S,,-reductase and 3,,-hydroxy 
steroid dehydrogenase activity in these cells. Whether this must be appreciated as a causative 
feature or merely as a result of earlier abnormalities remains unclear. However, androgenic 
stimulation can elicit the formation of new gland architecture only in tissues which already 
have that intrinsic capacity which is probably the result of a dysbalance in stromal to epithelial 
cell number as seen for instance in an androgen deprived (regressed) prostate, whether or not 
containing BPH nodules, or a ventral lobe of the rat's prostate implanted with urogenital sinus 
mesenchyme (Chung's model for BPH31). Androgen repletion restores the prostatic size to its 
precastration level but no growth beyond this threshold value will occur despite of prolonged 
administration of hormone. These findings suggest a permissive role for androgens in nodule 
genesis, Walsh and Wilsons7 were the first to demonstrate, however, that enlargement of the 
prostate, comparable to that seen in spontaneously occurring canine prostatic hyperplasia, 
could be produced experimentally by treating castrated dogs with 3,,-diol in combination with 
estradiol. These lesions were induced at a time when dogs normally have no indications of 
starting hypertrophy demonstrating that certain endocrine changes 'at puberty' could create a 
particular honnonal or biochemical environment which initiates the early cellular or molecular 
dysfunction that leads to hypertrophy". However, it still remained unclear whether the 
androgen or the estrogen was the main causative factor. 
On the other hand there are indications that another type of endocrine influence may be 
involved in the marked enlargement of nodules which is seen in the second stage of BPH 
evolution. The acceleration of growth of the glandular component appears to affect multiple 
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nodules nearly at the same time. This pattern suggests the possibility that some marked 
alteration in endocrine status occurs in most men in their seventh decade. It is of special 
interest that this condition becomes clinically manifest at a period in life when testicular 
function is declining. Despite a number of conflicting data on the plasma hormone levels that 
have been published in recent years" it is now generally believed that in older men the ratio 
free estradiol to free testosterone is increased in plasma60 . Taking into account the observed 
accumulation of estrogens in BPH tissue, especially in stromal nuclei61 , it is attractive to 
speculate about a stimulatory role for estrogens in BPH. 
Estrogens and stromal-epithelial relationship 
The male's estrogen production occurs mostly by extratesticular aromatization of 
androstenedione to estrone and of testosterone to estradiol. This conversion takes place in the 
peripheral tissues (e.g. adipose or muscle tissue), Some investigators found that this takes 
place in the prostate too, especially in the fibroblasts62 ,63, while others could not confirm these 
findings" . 
As we have seen in the previous sections of this paper many of the biological processes 
of epithelial tissue are indirectly controlled by androgens through androgen-dependent 
mediators of stromal origin. Although the presence of estrogen receptors is still under debate" 
(immunocytochemical assays in some cases have shown no staining6S) they appear to be more 
abundant in the stromaSJ.66-68, Similarly, by estrogenic stimulation the stroma could elicit an 
estrogenic effect on the epithelium by regulating the production of stromally-derived growth 
modulating factors, either stimulatory or inhibitory, and thereby exercising a paracrine 
influence on the adjacent epithelium, Indeed, a stimulation of the stromal compartment, in 
particular of the smooth muscle cells, could be observed after estrogen treatment69 , Here, 
interesting theories have been proposed to explain the observation that estrogens are capable of 
transforming prostatic smooth muscle cells into 'activated' smooth muscle cells7o,71, This 
concept has been developed from earlier observations on vascular smooth muscle cells, where 
a 'synthetic' phenotype was recognized in the developing organism and a 'contractile' state in 
the adult. The former phenotype has a fibroblast-like appearance, divides, and secretes 
extracellular matrix components72. An ultrastlUctural study on this phenomenon in the dog's 
prostate revealed that in the case of diminished androgen levels and increased estrogen levels, 
signs of metabolic and stmctuml alterations developed in the smooth muscle cells while similar 
alterations occurred in adjacent fibroblasts. Ultimately estrogen was identified as the compound 
inducing stmctural and functional dedifferentiation of prostate smooth muscle cells in castrated 
animals treated exclusively with estradiol". Furthermore, estrogen-mediated dedifferentiation 
was also observed in castrated dogs treated with an androgen that is readily metabolized to 
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estrogen. In the initial stages of this androstenedione treatment, alterations in smooth muscle 
cells were seen resembling those of the synthetic state of the vascular smooth muscle74 . In 
another study it was shown that concurrent treatment with the arolllatase inhibitor 4-0H 
androstenedione antagonized the estrogen-related effects on the prostate". However, Zhao el 
al. were not able to show similar changes in the rat ventral prostate76. 
From these data it is tempting to speculate that a changed endocrine situation leads to 
an increased number of 'activated' or 'synthetic' smooth muscle cells, affecting certain 
stromal-epithelial interactions which usually operate during the development of the prostate and 
resulting in BPH71 . However, comparative analyses of estrogen receptors (ER) in normal 
prostates, prostates causing no or only mild obstmctive symptoms (operated on for prostate or 
bladder cancer), and large BPH tissues revealed low ER numbers in normal prostate, highest 
concentrations in non-malignant stroma of non-obstructive prostates, and no ER at all in 
stroma of obstructive prostates 77. Brolin ef at. also found no ER staining in eight BPH tissue 
samples tested". The authors concluded that stromal growth in obstructive BPH may not be 
mediated via ER. However, it cannot be excluded that an increase of stromal ER concentration 
(as observed in non-obstnlctive prostates) is directly involved in induction of BPH, leading 
further prostatic growth thereafter into an estrogen independent state77 . 
In connection with this subject it is interesting to note that it has been suggested that 
dietary phytoestrogens may have a role in influencing growth regulation of the prostate. This 
could explain the difference in the incidence of prostatic disease found in Caucasians and 
Oriental people". 
2.5.2. Tissue interactions in carcinogenesis 
Since it has been shown that stromal-epithelial interactions continue to be of 
fundamental importance from fetal periods into adulthood, it is clear that these interactions 
could playa significant role in carcinogenic processes. While only little direct evidence for this 
idea is available on the prostate itself, there are several reports on other organ-systems 
supporting this concept. Some of them are outlined in Table I. The first four examples 
demonstrate the 'normalizing' effect of embryonic and normal stroma on neoplastic cells 
indicating that removal of certain physiological and selective pressure constraints can reverse 
the expression of previously malignant phenotypes and restores the celi to its normal 
phenotype, even though genetic changes that may have occurred during (multistep) malignant 
transformation. The next two studies depicted in Table I show the proliferation-inducing 
influence of 'transformed' fibroblasts on normal epithelia. Ali examples given illustrate the 
profound effects the stromal enviromnent can have on the epithelium. 
In another series of papers it was shown that the hormonal carcinogenesis in the female 
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genital tract exhibits a progression of events in which the stroma is definitely implicated6, 
Normally, the vaginal epithelium is dependent on estrogen for proliferation and cornification, 
However, if mice are injected neonatally with estrogens the vaginal epithelium becomes 
permanently cornified and hyperplastic throughout life even in the absence of ovaries, adrenals 
and pituitaries, It has been shown that persistent vaginal cornification is indeed estrogen-
independent and results from direct irreversible effects upon the vagina, This ovary-
independent persistent hyperplastic state is well recognized as an early stage in a series of 
events that ultimately lead to vaginal carcinogenesis, Biochemical and autoradiographic data 
demonstrate the lack of estrogen receptors in the epithelium so, at the time of treatment, they 
could only be detected in the stroma, Thus, the induction of ovary-independent persistent 
vaginal cornification is elicited neonatally at a time when estrogen receptors are present solely 
in the mesenchyme, even though the resultant abnormal proliferative state is ultimately 
expressed within the epithelium. These findings are consistent with the studies of androgen 
action on Tfm/wild-type tissue recombinants (see earlier sections), Tissue recombinant studies 
with vaginal stroma (VS) and vaginal epithelium (VE) derived from treated (EVS ; EVE) and 
untreated mice (VS ; VEl demonstrated that the stroma continues to play an important role in 
maintenance of this abnonnal state. The recombinants were grafted into ovariectomized hosts 
whose estrogen levels were so low as to result in atrophy of the host's vaginal epithelium, 
The EVS and EVE combination and the VS and VE combination responded as expected. with 
hyperplasia (85 %) and atrophy (83 %), respectively. However, the incidence of vaginal 
epithelial hyperplasia was about 60 % for both the EVS and VE and the VS and EVE 
recombinants. These findings demonstrate that as a result of neonatal estrogen treatment (when 
no estrogen receptors are present in the epithelium) permanent irreversible effects are elicited 
in both stroma and epithelium, apparently through direct effects on the mesenchyme and 
indirect effects upon the epithelium. Prins recently found similar imprinting features after 
neonatal estrogen exposure resulting in suppression of prostate growth and reduction of 
prostate responsiveness to testosterone in adulthood, The role of the stroma herein was not 
investigated however86. 
The relationship between the systems described above and prostatic carcinogenesis is 
uncertain but there are important parallels between the prostate and the other systems 
mentioned. Indeed, several studies on stromal-epithelial interactions in prostate cancer support 
this concept. For instance, Fujii and coworkers showed the (fetal) mesenchyme-induced 
conversion of bladder carcinomas to glandular structures resembling prostatic carcinoma ill 
ViV087 • while recently Chung and coworkers showed a marked inhibition of the growth of a 
hOlmone independent rat prostatic tumor cell line (Nb-102-pr) when grafted in combination 
with urogenital sinus mesenchyme, In some tumors urogenital sinus mesenchyme was found to 
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induce histomolphological changes toward more differentiated forms resembling that of the 
adult gland. ss,89. These findings demonstrate the continuous regulating influence of stroma on 
the (neoplastic) epithelium, 
Table I. Stromal-epithelial interactions in carcinogenesis 
Tissue combinatioll 
mammary carcinoma 
cells 
basal cell carcinoma 
cells 
human cancer cell 
lines 
basal cell carcinoma-
derived fibroblasts 
bladder carcinoma cell 
line 
psoriasis derived 
cOimective tissue 
embryonic mammary 
mesenchyme grafted 
in situ 
embryonic manunary 
mesenchyme 
normal mesenchyme 
human embryonic 
fibroblasts 
normal epidermal cells 
urogenital sinus conditioned 
medium 
normal epidermal cells 
mammary tumor virus 
bearing mice 
Observation 
reduction of epithelial 
proliferation; more orderly 
epithelial architecture7" 
complete loss of malignant 
phenotype, return to normal 
epithelial differentiationSO 
(coculture) degeneration of 
tumor cells81 
growth promoting activity%2 
decrease in cell proliferation; 
altered morphology, protein 
synthesis and secretionS) 
strong epidermal 
proliferation~ 
latency period of appearance 
of maillillary tumors reduced85 
The idea that both the epithelium and the stroma must be considered as potential sites 
of action in carcinogenesis has gained relevance by the following reports. On the one hand, 
Pritchett and coworkers found that cocuitures of epithelium derived from invasive bladder 
carcinoma with normal bladder stroma resulted in a remarkable increase in epithelial cell 
proliferation compared to epithelium derived from a (non-invasive) papillary bladder carcinoma 
or from a normal bladder90 , These findings suggest a primary epithelial abnormality as a cause 
of 'aggressive' growth, rendering the cells more susceptible to growth promotion by the 
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normal fibroblasts. On the other hand however, it was shown by Hodges and colleagues that 
cell surface markers characteristic of bladder carcinoma can be experimentally induced in 
normal (untreated) bladder when it is associated with bladder stroma previously treated with a 
carcinogenic agent91 , showing again the profound effect the stroma can have on the epithelium. 
Later on Oishi and associates92 reported the altered surface properties of fibroblasts associated 
with prostatic carcinoma, indicating that there is definitely 'something going on' in the stromal 
part of this epithelial neoplasm. Indeed it was observed by several authors that the fibroblasts 
of different primary tumors exhibit features reminiscent of their fully malignant neighboring 
cells9J . Thompson and coworkers studied a mouse prostate reconstitution model, which allows 
the introduction of genes, singly or in combination, into cells derived from the urogenital 
sinus. These cells are then 'reconstituted' and grafted under the renal capsule. When /'as alld 
myc oncogenes were introduced into both the epithelial and the mesenchymal compartments, 
poorly differentiated adenocarcinomas resulted. Introduction of both oncogenes only into the 
epithelium produced mainly epithelial hyperplasia, while introduction of both oncogenes into 
the mesenchyme produced only mesenchymal dysplasia"'''. 
Recently, Chung and coworkers described the development of a mixed adenocarcinoma 
and fibrosarcoma as a result of inoculation of tumorigenic fibroblast and non-tumorigenic 
prostatic epithelium into the subcutaneous space of syngeneic rats96,97. The epithelial cells 
subcloned from these tumors remained non-tumorigenic. It was found that only the 
proliferation of fibroblasts could be stimulated by DHT ill vitro, while the epithelial cells were 
not responsive. Consequently, the in vivo (mixed) tumors were androgen responsive as well as 
the uniform fibrosarcomas formed after inoculation of fibroblasts only. In this model, prostatic 
fibroblasts determined epithelial growth, androgen responsiveness, and tumorigenicity. In 
another study they found that these tumorigenic rat prostate fibroblasts also accelerated the 
growth and shortened the latency period of different human epithelial tumors when co-
inoculated in athymic nude mice98 , Other inunortalized or transformed (non-tumorigenic) 
fibroblast cell lines were also capable of accelerating human epithelial tumor growth, resulting 
exclusively in carcinomas. An important and surprising observation was that lethally irradiated 
fibroblasts retained the potential to accelerate tumor growth. This result strongly suggests that 
components of the extracellular matrix may be able to initiate and/or promote epithelial 
proliferation during various stages of tumor formation. However, because viable fibroblasts 
were more efficacious, a continued production of tumor-promoting factors by the fibroblasts 
seems to be necessary to cause the maximal epithelial proliferation, 
Gleave et al. co-inoculated nontumorigenic human prostate cancer cells (LNCaP) and 
various tissue-specific fibroblasts subcutaneously in athymic mice. LNCaP tumors were 
induced most consistently by human bone fibroblasts and prostate fibroblast cell lines". These 
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observations illustrate the importance of stromal-epithelial interaction in prostate tumor growth 
and suggest that (tissue specific) extracellular matrix and paracrine-acting growth factors playa 
role in prostate cancer growth and metastasis. The findings also may explain why prostate 
cancer selectively metastasizes to the bone. In vitro shldies have demonstrated the stimulation 
of prostate cancer cells by bone marrow derived factors 1oo• Picard and coworkers reported the 
presence of growth factors in the conditioned medium of cultured embryonic fibroblasts that 
were capable of stimulating the growth and metastasis of a fat rhabdomyosarcoma cell line; 
another example of fibroblast-mediated tumorigenicitylOl. 
Even more intriguing than the above-mentioned data, indicating an involvement of 
stromal cells in the process of local malignant growth, are data pointing to deviations of 
fibroblasts at localizations unrelated to the tumor. Reports originating from several different 
laboratories indicate that skin fibroblasts from patients with common forms of epithelial 
cancers may display phenotypic characteristics generally associated with transformed or fetal 
cells or both93 •102 . In some cases it was found that tumor promoter alone induced neoplastic 
transfonnation, which may indicate that the fibroblasts existed in an initiated state. Schor and 
coworkers studied skin fibroblasts from patients with breast cancer, melanoma, polyposis coli, 
and retinoblastoma, and observed altered fetal-like migratory behaviors103.1()j. They were able 
to purify the migration-stimulating factor from the conditioned medium of these cells105 . This 
phenomenon was more prominent in patients with a positive family history of breast cancer 
and was also seen in unaffected first-degree relatives of patients. 
Schor and associates proposed two hypotheses on the relationship between malignant 
growth and generalized fibroblastic abnormalities lO6 . First, the genetic or epigenetic defect 
expressed by the fibroblasts may be similarly expressed by the target epithelial cell population. 
Alternatively, it is conceivable that deviant fibroblasts are dysfunctional in the sense that 
normal inductive interactions with incipiently malignant cells are disturbed. The implication of 
the second mechanism in carcinogenesis would be momentous. The propensity to get certain 
types of cancer would be partly determined by genetic or epigenetic conditions of the 
mesenchymal tissues. 
2.6. Discussion 
In an impressive series of experiments, Cunha, Chung and others have shown the 
profound influence of stroma on the epithelium. Several lines of evidence support the concept 
that a multitude of epithelial features are regulated by androgens indirectly through androgen-
dependent mediators of stromal origin, while a similar mechanism could be applicable to the 
37 
Chapter 2 
action of estrogens on the prostate. The ability of prostatic epithelium to respond to these 
inductors is manifested at all ages from fetal to adult. 
Current models of steroid hormone action envisage a direct interaction of receptor-
steroid complexes with genetic regulatory regions to control the expression of tissue-specific 
genes in adult epithelia. However, the mechanism of action of androgens must be expanded to 
take into account the interactions of both cell types that clearly act in concert to ensure the 
DOrmal development and function of the prostate. TenniswoodlOJ has proposed an interesting 
hypothesis about the role of stromal-epithelial interactions in the control of gene expression in 
the prostate which is outlined below and depicted in Figure 3. He presupposes the existence of 
a stimulation-feedback loop between the epithelial and stromal cells of the prostate. Three 
factors: two growth factors, namely a 'stromally derived growth factor' (SDGF) and an 
'epithelially derived growth factor' (EDGF), and one inhibiting factor, 'epithelially derived 
inhibiting factor' (EDIF) , together modulate gene expression in the prostate during 
development and adult function. In the normal adult gland the constitutive expression of EDIF 
by the epithelial cells would repress SDGF gene expression in the sttomal cells. This would 
prevent replication in both cells enabling them to express continually the genes for steroid 
metabolism and prostate specific secretory function, 
From this concept, it is also possible to explain the etiology of certain prostatic 
diseases as well as the heterogeneity of epithelial proliferation after androgen replacement. For 
instance, the EDIF loop may fail either due to loss of EDIF gene expression in the epithelial 
cells or to the insensitivity of the stroma to the effects of EDIF. This would lead to a 
continued synthesis of SDGF and the consequent uncontrolled replication in the tissue. This 
may be the case in BPH : the reawakening of 'embryonic features' could in fact be the 
continued inappropriate expression of these normal, regulatory genes, If the production of 
SDGF and EDGF is not coordinately regulated, the overproduction of one 01' the other would 
be expected to lead to hyperplastic structures that are either predominantly epithelial or 
stromal. 
However this hypothesis does not explain carcinogenesis in the prostate. To do this we 
have to postulate an autocrine loop in the epithelium or another route of escape. The 
expression of the gene for an 'epithelially derived epithelium growth factor'(EDEGF) could 
very well (at least partially) be triggered or facilitated by stromal factors as we might conclude 
from the data presented in this chapter. Since cancer cells metastasize without their associated 
stroma this loop ultimately has to be 'disconnected' from (prostatic) stromal influences to 
become autostimulatory. 
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Figure 3 The Tenniswood hypothesisI07[modified]. SDGF = stromally derived growth factor; EDGF = 
epithelially derived growth factor; EDIF = epithelially derived inhibiting factor, 
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The effects of DRT can be roughly divided into two categories: those responses 
required for the process of replication and those required for normal prostate function and 
secretionlO1 , These processes may occur at the same time in the prostate108, However, when 
castrated rats are treated with androgen. replication ceases when the prostate reaches a 
predetermined size. whereas the synthesis of secretory proteins either continues lOS or 
commences1O'. This suggests that these two androgen-dependent processes (replication and 
transcription) are controlled in fundamentally different ways. Indeed, Thompson and 
associates were able to show that the growth and differentiation of the prostatic epithelium can 
be uncoupledllO Later on, Darbre and King have been able to separate the androgen-regulated 
proliferation of breast cancer cells from the androgen-related morphological changes, 
indicating that in breast cancel', too, the two parameters are not totally interdependellt l1l , From 
this review we have learned that the androgen-induced proliferation of epithelium is possibly 
entirely mediated via the stroma. This idea was again supported by the observations made by 
Chang and Chung112 on cocultures of rat prostatic cells. Analogous observations have been 
reported on the estrogen-induced proliferation of norolai mammary epithelia113 ,114, Taking into 
account the fact that normal prostatic epithelial cells never have been shown to respond to 
androgen with proliferation ill vitroIl2 ,115-119, I would like to suggest that a proliferative 
response of cultured epithelial cells to sex steroids is a hallmark of transfOlmation and thus 
restricted to cancer cells 120,121. According to this theory the normal task of the androgen-
receptor complex in the epithelium would be the induction of nonnal cytodifferentiation and 
secretion. However, the results of the tissue recombination experiments using wild-type 
mesenchyme plus Tfm epithelium raise serious questions concerning the validity of such 
theories. These recombinants appear to form nonnal prostatic tissue in terms of its 
morphology, proliferative response to androgens, and contents of prostatic protein, yet its 
epithelium is devoid of androgen receptors. Unfortunately, there is as yet no definite proof that 
these recombinants synthesize all of the androgen-dependent epithelial secretory proteins 
characteristic of nonnal prostate. This has to be resolved before we can draw definite 
conclusions regarding these lests. 
The fact that in most patients prostate cancer is inilially androgen-dependent, for this 
reason, does not inevitably mean that the primary devialion look place in Ihe epithelial part of 
Ihe tumor. Theoretically there are different palhways leading to this status: 
I A primary defect in fibroblasts, inducing (uncontrolled) androgen-mediated 
proliferation of epithelial celis (for instance by production of slromally derived growth 
factors or aiteration of eXlracellular matrix); 
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2 A primaty defect in epithelial cells, making them more sensitive to this androgen-
induced proliferation mediated by the stroma; if we could culture them, such cancer 
cells would ( theoretically) not be stimulated by androgens; 
3 A primary defect in epithelial cells, causing them to proliferate in response to 
androgens; if we succeeded in culturing these cells, they would probably be sensitive to 
androgens. 
The last alternative especially would apply to the androgen-responsive metastases frequently 
found in these patients. However, eventually androgen-independent cell populations appear and 
will take over the clinical course, resulting in endocrine-independent disseminated disease. As 
indicated before, this has to be due to an epithelial aberration, for these cell metastasize 
without their supporting stroma. 
As can be concluded from these observations, the development of an androgen-
independent prostate carcinoma is considered to be a multi-step event. Whether or not each 
step is caused by a mutation (in the epithelium) remains to be determined. 
It is clear that much research has to be done before all questions will be answered. 
However, we have to be aware of the fact that a loss of coordination and alteration in the 
interactions between epithelial and stromal cells may play an important role in carcinogenesis. 
Unfortunately, detailed information on modes of action between cells of different types can 
only be obtained from in vitro systems. These models in their isolated stage may differ 
fundamentally from the complex pattern of in vivo interactions. If possible, the validity of the 
information obtained in such tests has to be confirmed by experiments performed on the in 
vivo system from which these tests originate. The essential difficulty was best put into words 
by Smithers l22 : fl Reduction gains precision about parts but at each step loses information about 
the larger organization it leaves behind." 
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Abstract 
The study of stromal-epithelial interactions greatly depends on the ability to culture 
both cell types separately, in order to pennit analysis of their interactions under defined 
conditions in reconstitution experiments. Here we report the establishment of explant cultures 
of human prostatic stromal cells and their immunocytochemical characterization. As 
determined by antibodies to keratin and prostate specific acid phosphatase, only small numbers 
«5%) of epithelial cells were present in primary cultures; subsequent passaging flll1her 
reduced epithelial cell contamination, Antibodies against intermediate filament proteins 
(keratins, vimentin, and desmin) and smooth muscle actin micro filaments demonstrated that the 
population of stromal cells cultured from benign prostatic hyperplasia and prostatic carcinoma 
differed with regard to their differentiation markers. Two contrasting phenotypes were 
identified in cultures derived from these two different lesions. One, exhibiting fibroblastic 
features, was predominant in cultures derived from benign lesions and the other, showing 
varying degrees of smooth muscle differentiation, was more abundant in carcinoma-derived 
cultures. These findings are indicative of a remarkable divergence in the stromal-epithelial 
relationships associated with these pathological conditions, and may provide us with a potential 
tool for snldying these processes. 
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Introduction 
Control of cellular proliferation in the prostate involves a complex interaction of 
different cell types with soluble peptide growth factors, (steroid) hormones, and constituents of 
the extracellular matrix, The central role of urogenital sinus. mesenchyme in prostatic ductal 
morphogenesis, epithelial growth, secretory cytodifferentiation and function has been clearly 
demonstrated. All these androgen-induced effects were shown to be mediated by mesenchyme 
in the perinatal period l . Further studies on tissue recombinants indicated that stromal-epithelial 
interactions have retained their integral role in the adult gland'. For example, although the 
androgen receptor is expressed in prostate epithelium, it is believed that the proliferative effect 
of androgen on epithelium in the adult gland is also mediated by the stroma'·4. 
Detailed studies require the capability to culture epithelial and stromal cells separately 
in order to permit reconstihltion and analysis of their interactions under deHned conditions. 
There have been several reports concerning primary culture of murine prostate epithelial) and 
stromal cells4-1 , while less information is available on ill vitro models derived from human 
tissue. Although several human prostatic carcinoma cell lines have become available during the 
past decade'·II, and methods were developed for primary culture of epithelial cells from nOlmal 
and diseased prostates!'-!', only a few papers have been published about studies using cultured 
human prostatic stromal cells. No studies have been conducted so far regarding the 
characterization of these cells, which were tentatively designated as fibroblasts, a nomenclature 
mainly based on cell morphology. 
Analysis of cytoskeletal proteins is commonly used to assess the differentiation state 
and the embryonic derivation of many cell types17-2o. The availability of antibodies against the 
intermediate-sized filament proteins keratin, vimentin, and desmin has made it possible to 
distinguish between cells with epithelial, mesenchymal, and myogenic differentiationls-n . 
Further characterization of stromal cells can be achieved by analysis of actin isoform 
expression23,24. These developments have recently led to the recognition of a phenotypic 
heterogeneity among fibroblasts, which might be related to different biologic behaviors". 
Fibroblastic cells have been found to express a repertoire of m.uscle differentiation features in 
physiologic as well as in pathologic conditions". Many human epithelial tumors, for instance, 
are associated with the appearance of these so-called myofibroblasts that are believed to be 
responsible for the frequent, excessive collagen deposition and tissue contraction referred to as 
desmopiasia25 . 
In this paper we describe the immunocytochemical characterization of explant cultures 
of human prostatic stromal cells. The presence of residual epithelial cells in these cultures was 
determined using antibodies to keratin and prostate specific acid phosphatase. Subsequently, 
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antibodies against other intermediate filament proteins and microfilament smooth muscle actin 
were used to investigate stromal cell cultures derived from benign prostatic hyperplasia (BPR) 
and prostate carcinoma (PC) in order to reveal possible phenotypic differences. Several 
cultures were tested at subsequent passages in order to monitor potential shifts in the 
expression of these markers during the course of subculturing, 
Materials and methods 
Human prostate tissues 
Wedges of human prostate tissue were dissected from benign hyperplastic nodules and 
prostate cancers obtained by open prostatectomy or transurethral resection, After removal of 
portions of tissue for culture, the remaining prostate was fixed in formaldehyde and serially 
sectioned. The histology of hematoxylin- and eosin-stained sections immediately adjacent to 
tissue removed for culture was reviewed, and the findings were correlated with the findings in 
the corresponding cultures. All six prostatic malignancies were moderately differentiated 
adenocarcinomas, except for PC 302 and PC 313, which were both poorly differentiated 
carcinomas. Benign prostatic hyperplasia (BPR) tissue explants showed glandular hyperplasia 
in all seven explants, while in samples PA 557 and PA 558 an additional fibromuscular 
hyperplasia was noted. 
Tissue explants and subcultures 
Tissue specimens were cut into small pieces of approximately 2 x 2 mm and placed in 
60 mm petri dishes (Nunc) containing Earle's minimum essential medium (Gibco Europe, 
Breda, Netherlands) supplemented with 10 % fetal calf serum (FCS)(Hyclone Laboratories, 
Logan, Vt), 2 Mm glutamine, penicillin (100 Vlml), and streptomycin (0.1 mg/m!) (all from 
Gibco Europe), Cultures were maintained in a humidified incubator at 37°C in 5% CO2/air, 
Medium was replaced twice a week. For subculture, cells were detached by trypsinization 
(0.05% containing 0.02% EDTA) (Gibco) and split in a 1:3 ratio as soon as monolayers 
became confluent. 
hnmunostaining procedures 
Cytospins of cultures were prepared after trypsinization. Following the preparation of a 
single cell suspension in culture medium, cells were washed and resuspended in phosphate 
buffered saline (PBS) at a final concentration of 10' cells/ml. Subsequently, 0.1 ml of this 
suspension was spun down in a cytospin centrifuge for 10 min at 150 g. Cytospin preparations 
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were dried in air, fixed in cold acetone (-20°C) for 10 min, and left to dry at room 
temperature. In order to preserve cell morphology during the procedure, some of the stromal 
cell strains were seeded on object slides and stained in situ after 2-3 days of culture. Cytospins 
and fixed cell preparations were stored at -200C until further use. As a control, skin 
fibroblasts (passage numbers 11-12) were treated similarly. Acetone-fixed BPH tissue sections 
were taken as positive controls for the applied antibodies. 
Table I. List of antibodies used. 
Antibody Antigen (reference) Source Dilution Supplier 
NCL-5D3 Keratins 8, 18 & 19 mouse llIO Euro-Diagnostics(Apeldoom, NL) 
-acinary epithelium 26 
RGE53 Keratin 18 llIO 
-luminal cells 17 
RKSE60 Keratin 10 1110 
-squamous epithelium 21 
RCK103 Keratin 5 115 Dr. FeS Ramaekers, Dept. of Pathology 
-basal cells 27 University of Maastricht (Maastricht, NL) 
(X-PSAP Prostate spec. acid phospho rabbit" llI,OOO Dept. of Pathology, Erasmus University 
-prostatic glandul. epith. 28 (Rotterdam, NL) 
F39.4 Androgen receptor 29 mouse 1110,000 
lA4 a-Smooth muscle actin 1/60,000 Sigma (St Louis, USA) 
-smooth muscle cells 13 
Mon~ Desmin 1/15 Sanbio (Uden, NL) 
3001-5 -muscle cells 
PYI Vimentin 30 rabbit" 1115 Euro~Diagnostics (Apeldoorn, NL) 
" monoclonal antibody; ", polyc1onal antibody 
The slaining procedure included preincubation with blocking semm to reduce 
nonspecific staining. Nonimmune swine semm (DAKO, Denmark) was used for polyclonal 
antibodies, and nonimmune rabbit serum (DAKO) was used for monoclonal antibodies. Both 
sera were diluted ten times in PBS before use. Object slides were then incubated with the 
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specified antibody (see Table I) for 30 min at 37°C at the indicated dilution. We used rabbit 
antimouse peroxidase (DAKO) as secondary antibodies, diluted 11100 and containing 2% 
nonimmune rabbit serum, and swine antirabbit peroxidase (DAKO) , diluted 11100, for 
monoclonal and polyclonal antibodies, respectively . All dilutions of sera or antibodies were 
prepared with PBS (ph 7.2), except for polyclonal antibodies, which were diluted in PBS 
containing 5% bovine serum albumin (BSA). The peroxidase activity was visualized by DAB 
and hydrogen peroxide. All samples were counterstained with Mayer's hematoxylin. 
Cell counts 
Scoring of positively stained cells was done by one investigator, at lOOx magnification, 
At least 500 cells were counted per sample. Differences between groups were considered 
statistically significant if a P value ,;0.05 was found using the Wilcoxon rank test (Mann-
Whitney). 
Results 
Explant cultures of prostatic tissue gave rise to an initial halo of epithelial cells within 
a few days. After approximately I week, the first strands of fibroblastic cells could be seen 
growing out of the tissue blocks. During the following weeks, epithelial cells became 
increasingly overgrown by stromal cells. Subculturing after trypsinization appeared to promote 
stromal cell growth and to reduce epithelial cell contamination. At low density, the stromal 
cells had a flattened irregular polygonal appearance, while at confluent culture they showed a 
more spindlelike morphology and fOimed dense aggregates of elongated cells into fan-shaped 
bundles (Fig. I). No morphological differences were observed between cultures derived from 
malignant and nonmalignant lesions, Doubling times of the established stromal celJ strains 
varied between two and four days, 
In order to assess the extent of epithelial contamination of stromal cell cultures, 
epithelium-specific antibodies were applied to cytospin preparations and to cultures grown on 
glass slides. After three or more passages, prostate specific acid phosphatase, a marker of 
glandular epithelium known to be expressed in vitro16 , was not detectable in our cultures 
(Table II). Similarly, no androgen receptor (AR) positive cells were detected, even though in 
BPH tissue sections some of the stromal cell nuclei reacted with the AR-specific antibody (not 
shown). Since epithelial cells are known to express keratins as well during ill vitro culture, 
keratin antibodies have been used to evaluate prostatic epithelial cell cultures derived from 
human tissues 15,16, To confirm that the ratio of epithelial/stromal cells shifts in favor of the 
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Figure 1. Stromal cell culture derived from malignant prostatic tissue (fifth passage). Giemsa staining, 
magnification lOOx. 
stromal cells with increasing culture time, primary cultures were harvested after 1 week when 
the initial outgrowth of solely epithelial-like cells was seen (PA 555 = positive control), other 
cultures were trypsinized after several weeks, giving the fibroblasts enough time to crowd out 
epithelial cells (PA 544, PA 546, PC 302, PC 303 = negative controls). The remaining 
cultures shown in figure 2 were trypsinized after an intermediate period of time; both 
fibroblasts and epithelial cells were recognized by phase contrast microscopy. Cytospins 
prepared from the cultures were stained with the NCL-5D3 antibody, which is specific for 
keratins of glandular epithelium. As a result, only a small fraction (1.0-4.2%) of the cells from 
long-term primary cultures showed a positive reaction with the NCL-5D3 antibody, whereas in 
early stage PA 555 (positive control) more than 98% of the cells were keratin positive (Fig.2). 
Primary cultures that were scored after 2-3 weeks showed intermediate levels of epithelial cell 
contamination. However, at subculture, the epithelial cell number rapidly decreased, as 
illustrated by culture PC 313 in Figure 3. To exclude the possibility that epithelial cells had 
escaped identification due to a change in chain-specific cytokeratin expression during ill vitro 
growth, other keratin-specific antibodies were applied as well. As no staining was detected 
with these antibodies (Table II), it became unlikely that, for instance, morphologically atypical 
basal cells reactive with RCK103 or cells with squamous metaplasia reactive with RKSE60 
were present. 
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Table II. hllIllwlocytochemical analyses of prostatic stromal cells cultured and fixed on object 
slides 
Alltibody 
A Epithelial markers 
NCL-SD3 Acinary epithelium 
RGES3 Luminal cells 
RKSE60 Squamous epithelium 
RCK103 Basal cells 
a-PSAP Prostate specific acid phosphatase 
F39.4 Androgen receptor 
B Stromal markers 
lA4 o:-Smooth muscle actin 
Mon-3001-S Desmin 
PVI Vimentin 
BPH-
tissue 
+' 
+3 
+' 
+' 
+3,5 
+' 
+' 
+' 
COlltrol 
Skin-
fibroblasts2 
+ 
Stromal cell 
cuihlres1 
+ 
+ 
+ 
I At least 4 different celJ 'strains' were tested at passage # 2-8; 2 Passage number 11-12; 3 Glandular 
epithelium; 4 Basal cells~ 5 Stroma, 
All six stromal cell strains tested, as well as control cultures of skin fibroblasts, were 
strongly stained by vimentin antibody (Table II). Cytospin preparations of four more 
carcinoma-derived and four BPH-derived cultures also contained over 95% vimentin-positive 
cells. Cytospins of the keratin positive epithelial outgrowth of explant PA 555, however, 
showed similar numbers of cells reacting with vimentin antibodies. 
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100 Keratin 0 Desmin PA 555 100 Ep,thel,o..m 
t: 80 80 
~ 60 .. 60 + 0 
• 'V > 40 40 ~ 
0 0 
'" 
a. 20 20 
J- 0 ~ 0 0 PC BPH PC BPH 
100 8M Actin 
• PC 302* + 
. 
PA 544 
t: 80 ~ . PC 303 PA 546 ~ 60 .. PC 313 PA 555 0 
'l • PC 413 0 PA 557 :~ 40 
• PC 415 PA 558 0 ~ a. 20 PC 421 PA 559 
0 PA 560 PC BPH 
Figure 2. Immunocytochemical detection of keratins (NCL~5D3 antibody), desmin, and a-smooth 
muscle (SM) actin in cytospins prepared from the first outgrowth (passage nr 1) of stromal cells from 
malignant (PC) and benign (BPH) prostatic tissue specimens in explant culture. "; left to crowd out 
epithelial cells. Desmin content PC > BPH: psO.05 and a~SM actin content PC > BPH: psO.Ot 
(Wilcoxon rank test, n= 13). 
Using cells cultured on glass slides, desmin antibodies stained a fine network of mainly 
longitudinally mnning filaments covering the entire cytoplasm in all cell strains (Fig.4). In 
cytospin preparations, the average number of desmin containing cells was estimated to be 
21.5% (median, 17.9; SD, 19.7) for carcinoma- and 4.6% (median, 1.4; SD, 7.7) for BPH-
derived cultures (Fig.2). This difference in desmin positive cells proved to be statistically 
significant (P';O.05) using the Wilcoxon rank test. The percentage of positively stained cells 
was relatively constant over several passages (Fig.3). To this end, cell strains were maintained 
in culture up to six months. 
The lA4 antibody, directed against ,,-smooth muscle (SM) actin, stained more coarse 
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longitudinal fibrillar stlUctures in the cytoplasm (Fig.4). In primary cultures, the average 
number of positive cells in carcinoma-derived cultures (mean, 75%; median, 73.6; SD, 7.4) 
was significantly larger (P;O;O.OI) than the number in BPH-derived stromal cell culnlres 
(mean, 25.6%; median, 21.0; SD, 15.8). These differences, however, were only manifest 
during early passages. At subculture, the percentage of c<-SM actin positive cells in BPH-
derived stromal cell cultures increased, whereas in carcinoma-derived cultures the number of 
positive cells generally declined (Fig.3). 
100 Keratin 100 Desmin 
~ 80 80 
!!2 60 60 +jV ____ V v u +~ ~V v > 40 40 
.-------+ ., 
.~ 
.~ + 0 ,---------"- 20 20 .~----....... + 
~V :: + ...... ------~. . .. ·{S • 0 0 
1 2 3 4 5 6 7 2 3 4 5 6 7 
100 8M Actin Passage nr 
• 
~ 80 
v ---------v __________ V .,. PC 302 
!!2 60 + -'1- PC 303 v 
f', +~ u 
v / .~ 40 + ________ 4& .... + -1- PC 313 .~ .+~ 0 
0. 20 4& 
Ii PA 544 
+ 
0 PA 546 2 3 4 5 6 7 
Passage nr 
Figure 3. Immunocytochemical detection of keratins (NCL-5D3 antibody), desmin, and a-smooth 
muscle actin in cytospins prepared from stromal cell cultures at subsequent passages of ill vitro culture. 
': left to crowd out epithelial cells. 
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Figw'e 4. Immunocytochemical staining of desmin (A), and a-smooth muscle actin (B) in prostatic 
stromal cells cultured on object slides at low density, Magnification 400x, 
Discussion 
The results presented in this paper show the relative ease with which stromal cell 
cultures can be obtained from prostatic tissue explants, After a few weeks, the rich culture 
medium selectively stimulates stromal cell proliferation and gives rise to an overgrowth of 
these cells at the cost of the initially appearing epithelial cells, As determined by 
immunocytochemical analysis of keratins in cytospins, such stromal cell outgrowths contained 
less than 5 % epithelial cells during the first passage, Usually this low number of 
contaminating epithelial cells decreased even further in subsequent subcultures (Fig.3), In fact, 
epithelial cells were not detected by microscopy or cytokeratin staining after the second 
passage, It is needless to say, that the epithelial cell content of the first harvest depends on the 
time spent waiting for the stromal cells to crowd out the epithelial cells (see also Fig,2), Since 
trypsinization and subcultivation in our hands appeared to be selective in favor of the stromal 
cell population, subcultures were usually initiated at an early stage, 
Mesenchymal cells are known to express vimentin as intermediate-sized filament 
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protein!8-22 _ However, it was shown by others that nonmesenchymal cells can also express 
vimentin during in vitro culture3!, Since we experienced this to be tme for our primary 
cultures of prostatic epithelium (PA 555: 98% keratin-positive as well as 95% vimentin-
positive cells), the results obtained with anti-vimentin antibodies are of limited value for the 
characterization of cultured prostatic (stromal) cells. 
Fibroblastic cells, though traditionally considered to have a relatively common 
morphology in culture, are endowed with multiple functional properties; they play an essential 
role in the synthesis and regulation of extracellular matrix components, contribute to wound 
healing, and are involved in the pathogenesis of fibrotic processes", and probably in 
neoplasiaJ3 , Characterization of intermediate filament proteins and contractile proteins has 
shown to be a useful approach in differentiating fibroblastic phenotypes"'''. Defined subtypes 
have been found to express both vimentin and desmin in vivo, suggesting that some stromal 
cells are equipped with muscular elements and might participate in wound closure and visceral 
contractionJS ,36, For example, immunohistochemical studies have revealed that some testicular 
stromal cells have muscular phenotypic features, supporting the assumption that these myoid 
cells might influence the migration of sperm". Recently, a remarkable morphological and 
functional similarity was demonstrated between these rat testes-derived peritubular cells, and 
rat prostatic stromal cells in culture7 , Furthermore, the determination of cytoskeletal proteins 
in stromal cells associated with pathologic conditions has revealed a spectlUm of phenotypes 
that have not yet been found in normal tissues". On one hand, these findings support the 
possibility that certain epithelial neoplasias affect the growth and differentiation of fibroblasts 
present in their immediate vicinity, Fibroblasts associated with lung, breast, and colon 
carcinomas, for example, have been shown to express (X-SM actin24,38, These tumor-associated 
myofibroblasts are thought to be responsible for the desmoplastic response to neoplasias"·". 
On the other hand, desmoplasia has been considered to arise in early stages of tumorigenesis24 : 
this led to the search for mesenchymal cells with smooth muscle cell differentiation features in 
relation to epithelial proliferations, thought to predispose to malignant transformation. 
Cytoskeletal analysis of specimens from colon, breast, and uterus, indeed, has revealed that 
the presence of a-SM actin-expressing mesenchymal cells may be a feature of premalignant 
lesions or intraepithelial neoplasia37 . A prominent role of the stroma in the pathogenesis of 
BPH nodules in the human prostate was proposed by McNeal more than a decade ago39 . 
Obviously, the immunocytochemical observations reported here carry great potential diagnostic 
and prognostic significance: if similar changes were to be reflected ill vitro, this would provide 
us with a potential tool for studying these (pathologic) phenotypes in detail. 
When we focus on our results regarding the initial outgrowth of the explants, a striking 
difference is noticed between cultures derived from BPH and prostatic carcinoma, Whereas 
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BPH-derived stromal cell cultures predominantly consisted of fibroblastic cells, stromal cells 
derived from malignant lesions showed smooth muscle differentiation, as was clearly 
demonstrated by the presence of smooth muscle a-actin protein in approximately 75% of the 
cells (Fig.2). This conclusion was further substantiated by the observation that these cultures 
also contained relatively high numbers of desmin positive cells (25%) compared to BPH-
derived cultures «5%). The observation that a substantially lower number of cells stained for 
desmin than for ,,-SM actin is in agreement with findings reported by Shapiro et al. 40. These 
authors showed that the percent area density of actin positive tissue in prostate biopsies was 
twice as large as the area density of the alltidesmin stained tissue compartment, which led to 
the authors' conclusion that antidesmin appears to underestimate the amount of prostate smooth 
muscle, 
Inununocytochemical evaluation of serial passages revealed that in BPH-derived 
culhlres, increasing numbers of cells stained positive for a-SM actin, whereas some of the 
carcinoma-derived cells became a-SM actin negative, resulting in a more even distribution of 
phenotypic markers in both culture types (Fig.3). One carcinoma-derived culture, however, 
retained a high level of a-SM actin expression during all seven passages tested, The 
pathological classification of the parental tumor did not provide any clues as to why these cells 
were able to maintain this highly differentiated state under circumstances in which most cell 
types show a tendency to dedifferentiate to a slate bearing more general mesenchymal 
properties41 , The shift in phenotype observed in our experiments might be due to the separation 
of stromal cells from the epithelium (which was still present inside the tissue explants) as a 
result of subculhlre, However, it is also possible that the changes observed were caused by 
extended cultivation as has been described by several authors I7 ,42,43, On one hand, it has been 
shown that a-SM actin negative fibroblasts from breast tissue undergo smooth muscle 
differentiation after 4 days of cultivation38 , On the other hand, vascular smooth muscle cells 
were shown to downregulate ,,-SM actin and thereby resemble myofibroblasts44 , as might have 
been the case in our cultures, It is therefore important to take into consideration in fuhlre in 
vitro studies that apparent fibroblasts may represent modulated smooth muscle cells44 , In this 
respect it is interesting that cultured lens cells gradually develop ,,-SM actin, despite the fact 
that they do not contain this protein ill vivo24 , However, as the difference in phenotypes 
between BPH and carcinoma-derived cultures may gradually fade at subculture, it should be 
recommended to carry out (coculture) experiments with stromal cells from the earliest passage 
possible. 
In conclusion, cultured human prostatic stromal cells are heterogeneous with regard to 
their differentiation markers. Two contrasting phenotypes, one exhibiting fibroblastic features 
and the other showing varying degrees of smooth muscle differentiation, were detected iu 
61 
Chapter 3 
primary cultures derived from lesions with clinically different behavior. The outgrowth of 
different cell populations under similar culture conditions is indicative of a remarkable 
divergence in the stromal-epithelial relationship between these two pathological conditions and 
may provide us with an excellent tool for studying these processes. The reciprocal interaction 
of these stromal cells with normal epithelium, for instance, tested in coculture experiments, 
might help us unravel the complex mechanisms leading to benign and malignant neoplasia. 
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Abstract 
The influence of prostatic stromal cells on the growth of the prostatic carcinoma cell 
lines PC-3 and LNCaP was examined. In a double layer soft agar system, clonal growth of 
both cell lines was inhibited by all prostatic stromal cell strains tested irrespective whether they 
were derived from malignant or non-malignant prostate tissue. Irradiated as well as quiescent 
stromal cells showed similar effects. The finding that growth was inhibited also in the presence 
of stromal cell conditioned medium suggests that the observed effect were mediated by a 
diffusible growth inhibiting factor. Organ-specific production was suggested by the observation 
that skin fibroblasts stimulated rather than inhibited PC-3 cell growth. These findings indicate 
a negative control of epithelial cell proliferation by prostatic stroma. 
66 
Negative groll'th (omro/ by prostatic stroma 
Introduction 
Maintenance of the differentiated stlUcture and secretory function of the prostate is 
known to be regulated by testicular androgens. Because of the remarkable capacity to induce 
regenerative growth of the prostate gland in castrated animals, androgens were thought to act 
as a mitogen for prostatic cells. However, efforts made to demonstrate a direct effect of 
androgens on normal prostatic epithelial cells failed to show such a mitogenic response1.4. 
Following the observation that epithelium looses its growth capacity when separated from the 
stromas, it has become increasingly clear that both autocrine and paracrine factors produced by 
epithelial and stromal cells may play an important role in the local control of prostatic growth. 
The direct importance of embryonic urogenital sinus mesenchyme in prostatic ductal 
morphogenesis, epithelial growth, secretory cyto-differentiation and function has been 
demonstrated convincingly6, Subsequently, it was shown that mesenchyme was able to induce 
further epithelial growth in adult glands of intact mice in a dose-dependent fashion'·8 , 
indicating that stromal epithelial interactions have retained their integral role in the adult 
prostate9 . For this reason, the development of cancer and other disease states is likely to 
involve a loss of coordination and alteration in these interactions lO , McNeal ll already suggested 
the reversion of prostatic stroma to an 'embryological state' inducing inappropriate epithelial 
proliferation in benign prostatic hyperplasia (BPH). Tenniswood12 hypothesized the production 
in the prostate of three growth-modulating factors that are controlling growth and 
differentiation. He also suggested that the development of BPH may be caused by continued 
elevated expression of one or more of these factors. 
Another intriguing observation is that, upon maturation, accessory sexual organs reach 
a typical size and weight which is characteristic for that particular organ6, Likewise, 
administration of testosterone to androgen deprived rats restores the size of the prostate to its 
normal precastration level and no overgrowth is induced even after prolonged administration i3 , 
Indeed, in intact adult rats androgen levels are high while prostatic epithelial cell proliferation 
is low and in balance with cell death14. The experiments performed by Cunha and Chung' 
indicated that epithelial growth and, therefore, absolute prostatic size was regulated by the 
amount of mesenchymal (stromal) tissue present. Several investigators have been searching for 
the molecular basis of this homeostatic constraint mechanism that curtails further increase in 
cell number once the gland has reached its normal size, Biochemical analyses have shown the 
presence of inhibitors in the prostate but, since these determinations were performed on tissue 
homogenates, it is still not clear whether these are produced in the stroma or the 
epitheliumIS ,16. 
The present study further explored the hypothesis of a negative growth control by the 
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stroma, Using a two layer soft agar coculture system we observed an inbibition of epithelial 
cell growth by prostatic stromal cells, The possible role of this negative interaction is 
discussed, 
Materials and methods 
Cen lines 
The human prostatic carcinoma cell lines PC-3 and LNCaP were used as a source of 
epithelial cells. The cells were maintained in monolayer culture and were used between 
passages 35-65 and 20-40, respectively, Human stromal cell strains were established from 
tissue specimens obtained at surgery or autopsy, Stramal cells were cultured fram benign 
prostatic hyperplasia (BPH), prostatic carcinoma (PC) and normal prostatic tissue (NP), All 
cultures were used between the 4th and 9th passage. Human non-genital skin (Hl) was used as 
source of non~prostatic fibroblasts. 
Culture media 
In liquid monolayer culture, PC-3 cells were grawn in RPMI 1640 (Gibco), 
supplemented with 7% fetal calf serum (FCS) (Commonwealth SelUm Lab,), 2 Mm glutamin, 
penicillin and streptomycin (Gibco), Stromal cells were grown routinely in Eagle's MEM 
(Gibco) with 10% FCS, 2 Mm glutamin, and antibiotics, Conditioned media (CM) were 
collected from confluent cultures which were maintained in RPM! 1640 plus 10% FCS and 
supplements as specified above, After three days the medium was collected, centrifuged at 
1900 g for 15 min, and stored at _80 0 C, 
Preparatiou of soft agar plates 
A bottom layer of 3 ml, consisting of 0,5% agarose (Bio-Rad, low gel temperature 
agarose) in RPM! 1640 with 20% FCS andlor horse serum, and supplements as specified, was 
poured into petri dishes (Costar, 60 llllll), This layer was allowed to solidify for 15 min at 4 0 
C. Subsequently a top layer of 2 ml of 0,3% agarase in RPM! 1640 plus 20% FCS, containing 
the PC-3 or LNCaP cells, was poured over the bottom layer and left to set in the same 
manner. 
In coculture experiments, varying numbers of stromal cells were seeded on the bottom 
of the dishes and incubated overnight in MEM with 10% FCS before preparation of the 
agarase layers, Cocultures with quiescent cells were obtained by directly suspending the 
stromal cells in the bottom layer agarose ('non anchored'), Viability of the cells was tested 
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with the Tlypan-blue exclusion test. In experiments with CM, bottom layers were prepared 
from mixtures of CM and RPMI 1640 plus 20% FCS or phosphate buffered saline (PBS) in 
various proportions. The layers were solidified with 0.5% agarose as described above. The 
plates were incubated for 10-14 days in an atmosphere of 5% CO, in a humidified incubator at 
37' C. 
Counting of colonies 
Plating efficiency (PE) was determined by counting the number of colonies of ;" 200 
~m in size within 20 squares of 25 mm' per dish. To this end, the petri dishes were placed on 
a grid and a binocular operation microscope with a graduated scale in one eye-piece was used 
(magnification: 50x). All counts were done by the same investigator (J.J.K.). Given values are 
means of triplicate cultures, except for controls (6 plates/test). The significance of difference 
between values of the experimental groups was calculated using Student's t test. Differences 
were considered statistically significant if the two sided p value was smaller than 0.05. 
Results 
Optimization of clonal growth 
The clonal growth of PC-3 in solidified medium was dependent on the selUm content, 
the species from which the semm was derived, and the concentration of glutamin. No 
differences were observed when either F-I2 or RPMI 1640 was used as the basal medium. A 
linear relationship between PE and FCS concentration was found in the range of 5 to 20% 
FCS. Partial or complete replacement of FCS by horse selUm caused the PE to drop 
considerably. Although colonies in this medium were numerous, the majority of these was too 
small to be counted. In RPMI 1640, supplemented with 20% FCS and 2 Mm glutamin, clonal 
growth of PC-3 cells proved to be optimal and PE ranged from 25-35% in different 
experiments. LNCaP cells plated in the same medium had a PE of about 10%. The PE 
obtained when 5.103 PC-3 cells were seeded in the top layer did not differ significantly from 
the PE scored with 104 PC-3 cells. 
Effects of cocultured stromal cells in monolayer 
Clonal growth of PC-3 cells was inhibited by coculture with human prostatic stromal 
cells. In Figure 1 the effects on the PE of PC-3 cells, exerted by mono layers of stromal cells 
derived from normal prostate (NP), benign prostatic hyperplasia (BPR) and from prostatic 
carcinoma (PC) are shown. In general, there was an evident decline of the PE in the presence 
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of increasing numbers of stromal cells. The maximal level of inhibition observed amounted to 
40% of the PE obtained in the absence of stromal cells. At lower cell densities, stromal cells 
derived from NP and BPH, showed a tendency to stimulate, while those derived from PC 
inhibited clonal growth at the same initial cell numbers. At higher cell numbers, no clear 
differences were observed between stromal cells derived from normal prostate, prostate 
carcinoma and BPH. 
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Figure 1. Effect of cocuItured fibroblasts (anchored) on the plating efficiency of PC-3 cells. In a two 
layer soft agar assay, the indicated number of fibroblasts, derived from normal prostate (NP), benign 
prostatic hyperplasia (BPH) and prostatic carcinoma (PC), was allowed to attach overnight to the 
bottom of the petri dish. Subsequently, the bottom layer and then the top layer, containing the indicated 
number of PC-3 cells, were prepared. A and B: indicates fibroblast cultures derived from different 
donors with the indicated pathology. All given values are means of triplicate cultures, except for 
controls (no fibroblasts inoculated) where six plates were counted. * : p~ 0.05 ; ** : p:::; 0.01. 
In order to exclude the possibility that the inhibition was due to depletion of the 
medium andlor accumulation of toxic breakdown products, 3 ml of fresh liquid medium 
(RPM! 1640 + 20% FCS) was added on top of the solid medium and changed twice a week. 
Figure 2 shows that no significant changes in clonal growth were induced by this treatment 
suggesting that the inhibition was caused by a diffusible inhibiting factor secreted by the 
stromal cells. 
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Figure 2. Influence of extra medium 
on plating efficiency of PC-3 cells 
cocultured with fibroblasts (anchored), 
On top of the upper layer, 3 ml of 
fresh medium was added and changed 
twice a week. Controls were the same 
as in figure 1. Bars are means + S. D. 
Effect of irradiated, and quiescent stromal cells 
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To study the effect of non-proliferating stromal cells on the clonal growth of PC-3 
cells, cells were either irradiated with 15 Gy before preparation of the agarose layers or 
directly suspended in the bottom layer. In the latter case, the 'non-anchored' fibroblasts were 
still viable but remained quiescent; no colonies were formed. In both types of experiments, 
growth of PC-3 ceHs was inhibited in proportion to the number of stromal ceHs present and to 
the same extent as in the presence of growing stromal cells (Figure 3). These results may 
indicate that secretion of the putative inhibiting factor is not dependent on cell proliferation. 
Figure 3. Effect of an irradiated 
monolayer of stromal cells [-e-] and 
quiescent (non-anchored) stromal cells 
[-0-] on the plating efficiency of PC-3 
cells, Both cultures were obtained from 
BPH tissue. Inoculum: irradiated _104 
PC-3 cells ; non-anchored - 2.5,104 
PC-3 cells. * : po;; 0.05 ; ** : po;; 
0.01; N~4. 
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Effects of conditioned medium 
In order to investigate the secretion of this factor further, conditioned media of stromal 
cell monolayer cultures were collected and tested for inhibitory activity. Media from NP, BPH 
and PC-derived stromal cells caused a dose dependent inhibition of the clonal growth of PC-3 
cells (Figure 4). Similar experiments performed with LNCaP cells gave essentially the same 
resuits (Figure 5). In these tests conditioned media were diluted with PBS; replacement of PBS 
by RPMI 1640 did not affect the PE of the PC-3 or LNCaP cells. Although the maximal levels 
of inhibition caused by conditioned media were higher than those found with cocultured 
stromal cells, the differences between the media conditioned by fibroblasts from different 
sources appeared to be similar in both experiments. CM of PC-3 cells showed no effect on the 
PE. Inhibition by CM obtained from non-confluent cultures was significantly less than that 
reached with eM from the same cultures after attaining confluence (not shown). 
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Figul'e 4. Inhibition of clonal growth of PC-3 cells by conditioned medium. Conditioned media were 
collected from monolayer cultures of stromal cells derived from normal prostate (NP), benign prostatic 
hyperplasia (BPH) and prostatic carcinoma (PC). After centrifugation they were diluted with PBS to 
obtain the indicated content of CM. The figure shows the plating efficiency compared to the control 
dishes containing exclusively PBS in the bottom layer. Inoculum: 5.103 PC-3 cells. The right part of the 
figure shows the effect of conditioned medium obtained from PC-3 cells on its own plating efficiency. 
Vertical lines represent S.D. *: ps 0.05; ** : ps 0.001.; N=4. 
Effect of nOll-prostatic fibroblasts 
To test organ specificity of secretion of the proposed growth inhibiting factor, CM 
from human non-genital skin fibroblasts (HI) was collected and tested. Conditioned media 
from early passage number HI fibroblasts showed stimulation up to 300% above control values 
(not shown). However, only fresh CM was shown to be mitogenic whereas stimulation was 
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lost upon freezing. Cocultured HI fibroblasts, tested in the same way as prostatic stromal cells 
(monolayer), exerted a striking stimulation of the growth of PC-3 cells (Figure 6). Inhibition 
of clonal growth by BPH stromal cells was detectable at an initial cell number of 10'. With 
this number of skin fibroblasts a (statistically) significant stimulation was seen reaching a final 
level up to 100% above the control values when 10' cells were seeded. 
Figure S. Influence of conditioned 
medium on the plating efficiency of 
LNCaP cells. Conditioned medium 
from BPH fibroblasts was tested as in 
figure 4. Inoculum: 5.103 LNCaP cells. 
Vertical lines indicate ± S,D, N =4. 
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From the present study it can be concluded that stromal cells, isolated from the human 
prostate and grown ill vitro, secrete a diffusible product that inhibits the clonal growth of the 
prostatic carcinoma cell lines PC-3 and LNCaP. Organ specific secretion is suggested by the 
observation that skin fibroblasts were stimulatory in these tests. Although the limited number 
of different prostatic stromal cell strains tested does not allow definite conclusions, it was 
noticed that carcinoma derived stromal cells inhibited PC-3 cell growth at lower numbers of 
cocultured cells than did those obtained from BPH specimens or normal prostates. At these 
low cell numbers, stromal cells from non-malignant prostates tended to stimulate clonal 
growth, However, at higher cell numbers no striking differences were observed between the 
maximal levels of inhibition reached. These observations strongly suggest the presence of a 
negative growth control of prostatic epithelium by the stroma. 
The idea that stroma not only induces a mitogenic response but can also act as a rein 
on the epithelium is supported by observations made on other organ systems. Negative 
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regulators of cell growth have been demonstrated in other fibroblast cultures!"!'. Several 
coculture experiments as well as ill vivo studies show the controlling influence of the stroma on 
the epithelial compartmentlO,20-24, Similar experiments carried out on the male genital tract fit in 
with these findings. Rowley & Tindall" found that diffusible factors produced by fetal 
urogenital sinus decreased the proliferation of bladder carcinoma cells in vitro. Recently Chung 
and coworkers26 showed a marked inhibition of the growth' of a hormone independent rat 
prostatic tumor cell line (Nb-102-pr) when grafted in combination with urogenital sinus 
mesenchyme. Indeed, those findings indicate that, in the urogenital tract, mesenchymal cells 
are capable of inhibiting epithelial cell proliferation. 
Figure 6. Plating efficiency of PC-3 
cells cocuJtured with stromal cells 
(anchored) from different tissues. 
Dishes were prepared as indicated in 
Figure 1. BPH: stromal cells derived 
from benign prostatic hyperplasia; HI: 
fibroblasts derived from non-genital 
skin. Inoculum: 5.103 PC-3 cells; 
N~4. 
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Initial number of fibroblasts 
Several investigators have studied the stromal-epithelial interactions in the prostate in 
vitro but their reports were mainly focused on the mitogenic influence of the stroma27.2g , Kirk 
and associates" showed an inhibition of PC-3 cell growth in a double layer soft agar system by 
lung fibroblasts, but so far no reports have been published on stromally derived epithelial cell 
growth inhibitors in the prostate. Kabalin et al." inoculated prostatic epithelial cells directly on 
a monolayer of prostatic fibroblasts and reported a striking stimulation of the clonal growth, 
especially at lower numbers of fibroblasts seeded. Interesting however, are the results they 
obtained by seeding higher numbers of fibroblasts. Coculnlres containing more than 104 
fibroblasts showed a marked inhibition of epithelial cell growth. These observation fit in 
remarkably well with our own findings. 
The presence in the prostate of TGF-B, a well known inhibitor of epithelial cell 
growth30 , has been demonstrated by the presence of their mRNAs 15 ,16, III vitro studies have 
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implicated TGF-B as a potent inhibitor of prostatic epithelial cells, both normal and 
malignant". Kyprianou and Isaacs" showed a (40-fold) increase of TGF-B mRNAs four days 
after castration. Androgen administration to 4-day castrated rats led to a marked decrease in 
TGF-B mRNA to a level comparable to its constitutive expression obtained in intact control 
animals, showing that expression of TGF-B is under negative androgenic regulation. Since 
these studies were performed on whole tissue homogenates, no conclusions regarding the 
source of TGF-B can be drawn from these tests. However, prostatic carcinoma cells have been 
shown to secrete TGF-B"·3J, while the secretion of TGF-B by fibroblasts from other organs is 
well documented too". The work presented here shows that prostatic stroma also is capable of 
secreting negative mediators of epithelial cell growth. During embryological development 
androgen receptors are only present in the mesenchyme" indicating that all the androgen-
induced events, like morphogenesis, proliferation and secretory cytodifferentiation, are 
mediated via the stroma'. Likewise, Chang and Chung' showed that androgen-induced 
epithelial proliferation in the adult rat prostate is mediated entirely through the stroma too. At 
this point it is tempting to speculate upon a similar role of the stroma in the castration-induced 
involution of the gland. Indeed, since castration-induced cell death mainly takes place in the 
epithelial compartment and the ratio of epithelial to stromal cells changes in favor of the 
stromal part, it is more obvious to assume that the increase in TGF-fi mRNA expression, an 
active process, takes place in the less affected cell type. Moreover, the fragmentation of 
genomic DNA of the epithelial cells, shown to be an early event in programmed cell death", 
argues against the possibility that a 40-fold rise in TGF-B mRNA level on day 4 is caused by 
transcription of epithelial DNA. Definite answers however, can only be expected from studies 
using ill situ hybridization techniques with TGF-B specific probes. 
From this point of view it would be very attractive to explain excessive i.e. neoplastic 
growth by a failure in this system which may normally regulate prostatic size. It could, for 
instance, be caused by a mutation in the epithelium rendering it insensitive to these factors37 . 
This would also explain why tumors are able to metastasize without their stroma. However, we 
are well aware of the fact that the experiments reported here were done ill vitro and cannot be 
extrapolated directly to the ill vivo situation. More likely, prostatic neoplasia is due to an 
imbalanced regulation of the reciprocal stromal-epithelial interactions, where inhibitory and 
mitogenic signals nOlmally act in concert. The observations on the process of castration-
induced cell death strengthen the importance of our findings. Further efforts will be made to 
um'avel the identity of this stromally derived epithelium inhibiting factor. 
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Abstract 
Stromal cells from the prostate were recently shown to inhibit clonal growth of the 
prostatic carcinoma cell lines PC-3 (hormone-independent) and LNCaP (hormone-sensitive) in 
coculture. The present study revealed that stromal cell-conditioned medium strongly inhibited 
proliferation of PC-3 and LNCaP cells when grown in monolayer culture. Antiproliferative 
activity was found to be reversible, and was produced specifically by prostatic stromal cells 
and not by stromal cells derived from skin, foreskin, uterus, kidney, and Wilms' nunor. 
Inhibition was not species-specific, since the cell lines AT-2.1 and MATLyLu, derived from 
the Dunning rat prostate tumor, were also sensitive. No inhibition, however, occurred on 
breast and renal carcinoma cell Jines, suggesting a prostate-specific action. The putative 
inhibiting factor(s) could be concentrated and partially purified by annnonium sulfate 
precipitation. The possible role in stromal control of epithelial cell proliferation is discussed. 
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Introdnction 
Since the observation was made that the epithelium loses its growth capacity when 
separated from the stroma', it has become increasingly clear that stromal-epithelial interactions 
play an important role in the local control of prostatic growth. The importance of embryonic 
mesenchyme in prostatic ductal morphogenesis, and epithelial cell growth and differentiation, 
has been demonstrated by a unique series of tissue-recombinant experiments2. Several 
observations have indicated that these interactions might have retained their integral role in the 
adult prostate as well',) , It is for this reason that the development of cancer and other disease 
states is thought to involve a loss of coordination in such interactions. McNeal' has already 
suggested the reversion of prostatic stroma to an 'embryological state', inducing inappropriate 
epithelial proliferation in benign prostatic hyperplasia (BPR). 
Upon maturation, accessory sexual organs reach a typical size and weight which is 
characteristic for those particular organs2. Likewise, administration of testosterone to 
androgen-deprived rats restores the size of the prostate to its normal precastration level withollt 
inducing overgrowth, even after prolonged administration'. At that stage, epithelial cell 
proliferation is low and in balance with cell death'. Experiments performed by Cunha and 
Chung' showed that epithelial cell growth and, therefore, absolute prostatic size was regulated 
by the amount of mesenchymal (stromal) tissue present. During embryological development, 
androgen receptors are present only in the mesenchyme, indicating that all androgen-induced 
events are mediated via the stroma2,3. Furthermore, it was also shown that in the adult rat 
prostate, the proliferative response to androgens was mediated through the stroma', At this 
point it is tempting to speculate upon a similar role of the stroma in castration-induced 
involution of the gland. Androgen-induced stromally derived inhibitors of epithelial cell growth 
would participate in keeping the delicate balance between cell proliferation and progranuned 
cell death. The observation that rat and human prostatic epithelial cells grown ill vitro are able 
to proliferate in senlln-free medium without the presence of androgens8-11 , while androgen 
ablation in vivo induces a marked regression of the glandular epithelium5, indicates a major 
role for the stroma in a negative control of epithelial cell proliferation. Several investigators 
have been searching for the molecular basis of this homeostatic constraint mechanism that 
curtails further increase in cell number once the gland has reached its predetermined size. 
Biochemical analyses have shown the presence of (polypeptide) growth inhibitors in the 
prostate but, since these determinations were performed on whole-tissue homogenates, it is still 
not clear whether these are produced by the stroma or the epitheliuml,.I3. 
The present study further explores the hypothesis of a negative control by the stroma. 
Using a two-layer soft agar assay, we previously observed an inhibition of the clonal growth of 
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human prostate tumor epithelial cell lines PC-3 (hormone-independent) and LNCaP (hormone-
sensitive) by cocultured prostatic stromal cells14 , To elucidate this interaction further, we 
established a number of stromal cell cultures from human prostatic carcinomas as well as 
benign prostatic hyperplasia nodules, and investigated the influence of conditioned medium 
(CM) of these cultures on the anchorage-dependent growth (monolayer cultures) of different 
epithelial cell lines from human and murine origin. Likewise, several nonprostatic stromal cell 
cultures were initiated, and their CM tested, The results demonstrated that only prostatic 
stromal cells accumulate inhibitory activity in the (conditioned) medium, Anchorage-dependent 
as well as anchorage-independent growth of prostatic carcinoma cell lines was inhibited in a 
dose-related fashion, The possible role of the stroma in a negative control of epithelial cell 
proliferation is discussed. 
Materials and methods 
Stromal cell cultures 
Histologically proven tissue specimens from benign prostatic hyperplasia (BPH) and 
prostatic carcinoma (PC), obtained by surgery, were cut into pieces (approximately I nml x 2 
mm) and placed in 35 mm petri dishes (Nunc) containing 1.5 ml basal medium: Earle's 
Minimum Essential Medium (Gibco Europe, Breda, the Netherlands) supplemented with 10% 
Fetal Calf Setum (FCS) (Biological Industries, Beth Haemak, Israel), 2 Mm glutamine, 
penicillin, and streptomycin (all from Gibco Europe), Cultures were maintained in a 
humidified incubator at 37 'C in 5 % CO,/air. Medium was replaced twice a week, The initial 
halo of epithelial cells grown from these explant cultures became overgrown with fibroblast-
like cells within several weeks, Subsequently, cells were detached by trypsinization (0,05% in 
0,02% EDTA)(Gibco Europe) and split in a 1:3 ratio every 2-3 weeks, In order to minimize 
the number of epithelial cells in our cultures (none were detected morphologically), we only 
used prostatic stromal cells of passage numbers 4-9 in this study, Using the monoclonal 
antibody NCL-5D3 (Organon, Oss, the Netherlands) reacting with Keratins 8, 18, and 19, we 
found the number of positive cells in these cultures (BPH as well as PC) varying between 0-
5 %, indicating that nearly all cells were of nonepithelial origin, Stromal cell cultures from 
skin, foreskin, utems, kidney, and Wilms' hUllor specimen were established in the same way. 
Cell lines. 
The prostatic carcinoma cell line PC-3, obtained from Flow Laboratories (Irvine, 
Scotland) and maintained in basal medium, was used between passage numbers 30-45, LNCaP-
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FGC cells (used at passage numbers 65-70), originally made available to us by Dr. 1. 
Horoszewicz (Buffalo, NY), and the Dunning rat prostate tumor cell lines AT-2,1 and 
MATLyLu, kindly provided by Dr. ],A, Schalken (University of Nijmegen, The Netherlands), 
were all cultured in RPM! 1640 (Gibco Europe) supplemented with 10% FCS, glutamine and 
antibiotics, The renal carcinoma cell line RC-21 , established at our laboratory, was cultured in 
basal medium, The breast carcinoma cell line MCF-7 (pass, nr. 330), generously given by Dr. 
P,M,J,J, Berns (Daniel den Hoed Cancer Center, Rotterdam, The Netherlands), was cultured 
in RPMI 1640 (Gibco Europe) containing 10% FCS, 2 ~g/ml insulin (Sigma, St Louis, MO), 
glutamine, and antibiotics. All cultures were shown to be free of mycoplasma contamination 
by staining with Bisbenzimide (Hoechst dye 33258) obtained from Sigma, 
Collection of conditioned medium (CM) 
Prostatic stromal cell conditioned medium (:::::: 0.2 mllcm2) was collected twice a week 
from confluent monolayers, After centrifugation (6,000 g; 20 min; 4°C), CM was stored at 
-20°C until further use, 
Growth inhibition assay 
Inhibition of anchorage-dependent cell growth was determined by means of a 
colorimetric assay based on the reduction of a tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MIT), to a colored formazan product (maximum absorption 
at 560 nnl) by mitochondrial enzymes present only in living, metabolically active cells15 , 
Results of these MTT-tests performed on prostatic epithelial cell lines were shown to correlate 
well with those obtained with ['Hl-thymidine incorporation assays and with direct DNA 
measurementsll,]s. Cells were harvested by trypsinization, resuspended in fresh culture 
medium, and plated in a volume of 0,1 ml per well in 96-well microtiter plates (Costar), 
Inoculum: 2,000 PC-3 cells per well, The next day (day 0), 0, I ml of sample Was added, 
resulting in a total volume of 0,2 ml, with a 50% dilution of the sample and a (basal) FCS 
concentration of 5 %, At day 3, 30 ~l of a 5 mg/ml solution of MTT (Sigma) in PBS was 
added to each well, After a 4-hr incubation at 37°C in 5% CO,/air, the medium was carefully 
drawn off and the purple dye was dissolved in 0,1 ml DMSO (Merck, Darmstadt, Germany) 
containing 12,5% of a 0,1 M Sorensen buffer Ph 10,5, Plates were placed on a plate shaker 
for 5 minutes, and the absorbance at 560 nm was read using a Flow Titertek Multiskan plate 
reader. Unless otherwise stated, eight replicate wells were used for each sample, Wells 
containing medium but no cells served as blanks. Results are expressed as percentage of 
maximal growth from day 0, obtained in fresh basal medium. To determine the number of 
cells at this point, one extra plate was used and (16 wells) read at day 0, 
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Growth curves 
Growth curves (Figure 1) were determined in the presence of CM previously dialyzed 
(Spectrapor 3-cutoff: 3500 Dalton; Spectrum Medical Ind., Los Angeles, CA) against basal 
medium without serum. In order to avoid the fonnation of a confluent monolayer, PC-3 cells 
were plated at a density of 1,000 cells/well. MTT-tests were performed on separate plates at 
the days indicated. 
Production of inhibitory activity 
Stromal cells were plated in 24-well plates in 0.6 ml (~ 0.3 mllcm') of basal medium 
and left to attach overnight. All wells were changed to fresh medium twice a week (days 1, 4, 
8, and 11). At the days indicated, CM was harvested from two wells, pooled, and stored at -
20'C after centrifugation. Subsequently, both mono layers were trypsinized and viable cells 
counted after addition of Trypan-blue, The average of these cell counts is given. After all 
samples were collected, inhibition of PC-3 cell growth by the respective CM was tested by 
means of the MTT-assay. 
Concentration and partial purification eM 
CM of different passages was pooled and fractionated by anmlOnium sulfate 
precipitation. This was performed through a stepwise increase in the level of saturation by 
adding solid ammonium sulfate (Sigma) to the medium at O'C under continuous stirring!'. At 
every 10% rise, the solution was centrifuged (10,000 g; 4 'C; 20 min) and the pellet dissolved 
in PBS (Gibco). During this procedure, Ph did not drop below 6.5. Samples from supernatant 
and pellet were extensively dialyzed (cutoff: 3.5 kD) at 4'C against PBS and MEM, 
respectively, and stored at -20'C after sterilization through a 0.45 I'm membrane (Schleicher 
& Schuell, 's-Hertogenbosch, The Netherlands). Osmolarity was checked to be 275-325 
mOsm, using a Roebling osmometer (Vogel, Giessen, Germany). 
Protein determination 
Protein concentrations were measured with the Bio-Rad Protein Assay Kit (Bio-Rad 
Labs, Veenendaal, The Netherlands). A 1:I-mixture of the albumin and globulin solutions was 
used as a standard. 
Statistical analysis 
All statistical comparisons were made using Student's t test analyses. Differences were 
considered statistically significant if the two-tailed P value was smaller than 0.05. 
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Results 
Effect of prostatic stromal cell CM on PC-3 cells in monolayer cuitures 
Anchorage-independent growth of human prostatic tumor epithelial cell line PC-3 was 
reported to be inversely correlated with the number of human. prostatic stromal cells present in 
coculture experiments. Furthermore, it was shown that stromal cell CM inhibited clonal 
growth of the hormone-independent PC-3 cells as well as the hormone-sensitive prostatic 
carcinoma cell line LNCap14. As is depicted in Figure lA, the anchorage-dependent culture 
(monolayer) of PC-3 cells was also inhibited by prostatic stromal cell CM. Growth inhibition, 
as determined by the MTT-test, of up to 45% was observed on the fourth day, as compared to 
growth in basal medium. At day I and day 2 the proliferation in CM was 53 and 55 % of the 
controls, respectively. Growth in phosphate buffered saline (PBS) was better than that found in 
dialyzed CM, indicating that the inhibition was not merely due to depletion of nutrients or 
mitogens from the medium, but was caused by diffusible growth inhibiting factor(s) present in 
the CM. Replacing CM with basal medium after I day incubation resulted in a growth rate 
similar to that of controls (Figure IB). At that time, CM had decreased cell number to 50% of 
the control, however, no 'catch~up' growth was observed. Similar observations were made 
when media were changed at day 3. These findings indicate that inhibition was reversible after 
removal of the antiproliferative stimulus. 
A 560 nm 
... 
A 
1.' 
c::::::J SI. 
m •• 0 .• 
c:::::::J PBS 
c=J eM 0.6 
0.' 
0.0 
0 2 4 0 1 2 • 4 
Time (days) 
Figure 1. A: Inhibition of PC~3 cell growth by prostatic stromal cell CM. The left axis gives the 
absorbance at 560nm as determined by the MTT test. Data labels on the right indicate the percentage of 
growth compared to proliferation in basal medium. B: Reversibility of inhibition. At day 1 or day 3, 
half of the cultures were changed to fresh basal medium, Cultures initiated with eM, ~.~. Cultures 
initiated with basal medium, ~o~, Continuous lines, no medium change. Dashed lines, medium change at 
day 1. Dotted lines, medium change at day 3, Inoculum: 1,000 cells/well. Error bar: SD. 
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Production of inhibitory activity by prostatic stromal cells. 
Figure 2, illustrating the 'kinetics' of production, demonstrates the positive correlation 
between the number of stromal cells present and the level of inhibition induced by their 
respective CM. About 30,000-40,000 cells/cm' were needed to induce a statistically significant 
inhibition (more than 15%) of PC-3 cell growth. This level of inhibition was reached at day 2 
and day 7, respectively, in cultures plated at high and low density. However, at higher cell 
densities (;0,50,00 cells/cm'), the correlation between cell number and inhibition no longer 
existed. Both cultures became density-arrested at the end of the second week. At this point, the 
graph shows that inhibitory activity still accumulated in time, illustrating its independence of 
proliferation as reported earlier14 . However, despite a clear difference in cell number, the CM 
caused equal levels of inhibition. Although the activity of the CM still appeared to be rising 
after four days, we considered this to be the maximal pedod for conditioning, for two reasons. 
First, after four days without medium refresiullent, the stromal cells appeared less viable. 
Some cells detached from the substratum and were washed away with the medium, as is seen 
on day 8. Second, maximal activity, present in medium covering a confluent monolayer of 
stromal cells, usually did not exceed the 45% level, irrespective of whether it was conditioned 
for four days or longer. The fact that concentrating the CM enabled us to obtain higher levels 
of inhibition (see below), indicated that this critical level was not due to limitations in our test 
system. 
In order to find out if the passage number of the stromal cell cultures affected activity, 
several cultures were initiated and maintained for several months. As is depicted in Table lA, 
levels between 35-45% inhibition were consistently found in CM from nearly all stromal cell 
cultures derived from both malignant (PC) and nonmalignant (BPH) prostates. However, no 
clear-cut differences in activity were seen between CM of subsequent passages. 
Production of inhibitory activity by non-prostatic stromal cell cultures. 
Table IE lists the growth of PC-3 cells in CM obtained from stromal cell cultures 
derived from skin, foreskin, normal utems, Wilms' tumor, and normal kidney tissue. Culhlres 
were initiated, subcultured, and CM tested in essentially the same way as prostate-derived 
culnlfes. No biologically significant inhibition of PC-3 cell growth occurred, especially if it is 
taken into account that 5-10% less growth inhibition was observed when depleted nutrients 
were replaced by dialyzing these samples against medium (not shown). These data 
demonstrated that induction of inhibitory activity was confined to prostatic stromal celis, 
strongly suggesting an organ-specific production. 
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Figure 2. Production of inhibitory activity by prostatic stromal cells. Cells were plated in 24-well plates 
at two densities: a) 10,000 cells!cm' (open symbols) and b) 1,000 cells!cm' (closed symbols). Medium 
was changed twice a week (A). At the days indicated, samples were taken and cell number counted 
(two wells). Left axis gives the number of stromal cells per cm2 represented by the dotted lines. Solid 
lines represent the inhibition of PC-3 cell growth by Ihe respective eM as shown on the right axis. As 
a control. basal medium was incubated without cells, centrifugaled and stored as CM. Levels of 
significance were calculated using these control values. Inhibition> 15% was statistically significant 
(P";0.05), while values >20% were highly significant (P";0.005). 
Concentration and partial purification of CM, 
In order to concentrate inhibitory activity, we performed an ammonium sulfate 
precipita(ion of CM. Figure 3 demonstrates that nearly all inhibiting activity was found in the 
pellet formed between 40-50% saturation. As a result, the remaining supernatant no longer had 
a negative effect on cell growth. These findings indicate that the inhibition was caused by 
precipitable factor(s) in the CM and was not due to depletion of nutrients or growth 
stimulating factors. Approximately 25 % of the total amount of protein originally present in the 
CM was delivered in the concentrated fraction, while 75% could be discarded. Essentially the 
same results were obtained when the number of steps was reduced (I.e., 0-40%, 40-50%, and 
50-100% saturation). Serial dilution curves of such a preparation are shown in Figure 4. 
Inhibition of PC-3 cell growth reached its maximum of approximately 60% compared to 
controls, at a protein concentration of 2 mg/Ill!. Using other, more concentrated preparations, 
inhibition levels of up to 90% were found at protein concentrations of about 4 mg!ml. In a 
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Table I. Inhibition of PC-3 cell growth by CM from different stromal cell cultures • 
A Prostate derived stromal cell cultures. B Non-prostatic stromal cell cultures. 
Culture Pass nr Number of % Culture Pass nr Number of % 
CM tested Inhibition CM tested Inhibition 
[average] [average] 
PA 517 5 11 40 HF 10.3 9 9 8 
PA 518 4 4 30 Skin 10 24 18 
6 9 40 11 13 13 
7 7 38 
8 14 37 FS I 3 2 7 
PA 519 6 11 45 Foreskin 4 6 14 
PA 520 4 8 39 
5 13 40 Ut 1 3 29 13 
6 9 41 Uterus 
7 25 48 
PA 526 3 5 39 WT3 4 9 17 
4 8 39 Wilms' tumor 
5 6 39 
PA 527 3 15 35 WT7 5 7 9 
4 13 38 Wilms' tumor 
PC 239 4 5 36 
5 6 32 NN I 3 3 16 
6 13 35 Kidney 4 3 9 
7 35 37 5 5 18 
PC 242 3 3 40 
4 7 40 
5 37 43 
PC 245 4 10 38 
5 10 42 
PC 259 4 13 32 
* Cultures were initiated and subcultured as described in Materials and Methods. Twice a week, CM 
from confluent monolayers was harvested and fresh medium given. Centrifuged eM was stored at 
_20DC. Within 4 weeks, the antiproliferative effect of these undialyzed samples was measured. 
PA, Benign prostatic hyperplasia; PC, Prostate cancer. 
comparative experiment, bovine serum albumin (BSA) was shown to interfere with cell growth 
only at higher concentrations: approximately 10% inhibition at 6 mg/m!. These findings 
indicate that the observed inllibition of semipurified inllibitor was not merely due to a high 
protein content. Basal medium and skin-derived stromal cell CM were fractionated by the same 
procedure in order to investigate the possibility that the observed effects were caused by 
concentration and/or activation of serum-derived growth inhibitors. The effect of these 
preparations on cell growth (tested at concentrations up to 6 mg/ml) did not differ significantly 
from control cultures, again indicating that inllibition caused by prostate stromal cell CM was 
not due to a high protein concentration. 
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Figure 3. Concentration of inhibitory 
activity by ammonium sulfate 
precipitation. The saturation level was 
increased stepwise and the effect of 
pellet and remaining supernatant tested 
on PC-3 cell growth after dialysis 
(open dots and left axis), The amount 
of protein in the pellet is given as a 
percentage of the total protein present 
in the original solution (closed dots and 
right axis), 
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Figure 4. Serial dilutions of concentrated CM (pellet 40-50%) on (A) human prostatic carcinoma cell 
lines PC-3 (-0-) and LNCaP (-111-), and (B) cell lines from the Dunning tumor (rat pros,ate) AT2. i 
(-0-) and MATLyLu (-111-). Inoculum: PC-3, 2,000; LNCaP, 5,000; AT2.! and MATLyLu, 2,000 
cells/well. Bars, SD. 
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Inhibition of epithelial cell lines. 
As shown in Figure 4A, different human prostatic carcinoma (epithelial) cell lines were 
inhibited when grown in monolayer culture. Anchorage-dependent growth of both the 
hormone-insensitive cell line PC-3 and the androgen-responsive cell line LNCaP was inhibited 
in a dose-related fashion. Figure 4B illustrates that similar results were obtained with 
epithelial cell lines AT-2.1 and MATLyLu, derived from the Dunning rat prostate tumor. 
These findings indicate that the growth-inhibiting factor present in the CM did not have a 
species-specific effect. Preliminary tests on primary epithelial cell cultures (second passage) 
derived from BPH and prostatic carcinoma, showed these cells to be inhibited as well. Growth 
assays performed on the human breast carcinoma cell line MCF-7 as well as on the human 
renal carcinoma cell line RC-21 did not show inhibitory activity (Figure 5). These findings 
suggest that CM-derived inhibition may be prostate-specific. 
2 •• A: 3.2 mg/ml 
B: 1.6 mg/ml 
2 •• 
~ , .. 
.c 
~ 
0 , .. 
-
c: 0.8 mg/ml ~ 0: 0.4 mg/ml 
r T ...I-fI- = 
I 
C!J 
•• 
A B C D A B C D 
• MCF-7 RC-21 
Figure 5. Serial dilutions of concentrated inhibitor on the breast carcinoma cell line MCF-7 and 
the renal carcinoma cell line RC-21. Inoculum: MCF-7, 3,000; RC-21 , 10,000 cells/well. 
Bars, SD. 
Discussion 
Cellular proliferation in the prostate is controlled by a complex interaction of different 
cell types with soluble peptide growth factors, (steroid) hormones, and constituents of the 
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extracellular matrix. It is likely that the array of peptide factors which play a role in the 
regulation of cell atlaclUllent and proliferation affects these processes through both positive and 
negative control mechanisms. Several epithelial cell growth-promoting peptides have been 
identified in the prostate and in prostate-derived epithelial cell cultures17•l8 ; some of them have 
been positively identified as also being produced by stromal cells, suggesting a role in stromal-
epithelial interactions 19-21 • Following the observation that urogenital sinus mesenchyme plays a 
major role in the androgen-induced development of the gland', stroma has been recognized as 
a potential site of disregulation of epithelial cell growth, which may eventually lead to 
neopJasia22 . The fact that prolonged androgen administration to castrated animals does not 
induce the gland to grow beyond its predetermined size', together with the observation that 
withdrawal of androgens decreases epithelial cell number only in the in vivo situation where 
stroma is present8.5 , suggests a role for stromally-derived epithelial cell growth inhibitors in the 
prostate. 
The results presented in this paper suggest that prostatic stromal cells secrete a 
diffusible epithelial cell growth inhibitor(s). Anchored, as well as nonanchored, growth of the 
hormone-independent prostatic carcinoma cell line PC-3 and the androgen-responsive prostatic 
carcinoma cell line LNCaP was affected. Primary epithelial cell cultures from BPH and 
prostate cancer appeared to be sensitive as well. Accumulation of anti proliferative activity in 
the CM was positively correlated with cell number and confined to prostate-derived stromal 
cells. This organ-specific production appears to be a unique property, for it has not been 
described before in prostate research. Characterization currently underway shows that the 
putative factor appears to be a protein with a molecular weight > 3.5 kD, sensitive to reducing 
agents, indicating the presence of S-S bridges that are needed for biological activity". Several 
aspects concerning the production are still under investigation. For the present, serum-derived 
factors are required for optimal production andlor secretion. Preliminary results in our hands 
failed to show signiticant effects of steroids (testosterone, dihydrotestosterone. or estradiol) in 
this respect, however. 
That stroma not only induces a mitogenic response, but can also act as a 'brake' on the 
epithelium. is suggested by observations made on other organ systems. Negative regulators of 
cell growth have been demonstrated in other fibroblast cultures"'''. Several coculture 
experiments as well as in vivo studies showed the controlling influence of the stroma on the 
epithelial compartment27, ranging from induction of differentiation28.29 • to tumor cell 
degeneration.3o. Similar experiments carried out on the male genital tract fit in with these 
findings. Rowley and Tindall" found that diffusible factors produced by fetal urogenital sinus 
decreased the proliferation of bladder carcinoma cells ill vitro. Recently, Chung et 01.31 showed 
a marked growth inhibition of a hormone-independent rat prostatic tumor cell line (Nb-102-pr) 
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when grafted in combination with urogenital sinus mesenchyme. Hayashi and Cunha:n, 
performing similar experiments on Dunning R3327 rat prostate tumor lines, demonstrated a 
reduction in epithelial cell growth rate and an apparent reduction or loss of tumorigenesis of 
these cells, Indeed, those findings indicate that, in the urogenital tract, mesenchymal cells are 
capable of inhibiting epithelial cell proliferation, 
Several investigators have studied stromal-epithelial interactions in the prostate ill vitro, 
but their reports were mainly focused on the mitogenic influence of the stroma34-36.19,21. Kirk ef 
ai," showed an inhibition of PC-3 cell growth by lung fibroblasts, using a serum-dependent 
soft agar assay, So far, no reports have been published by other groups on stromally-derived 
epithelial cell growth inhibitors in the (adult) prostate, Remarkably, however, all studies 
demonstrating stromal stimulation of prostatic epithelial cell growth were performed under 
serum-free conditions, Regarding the lack of a growth stimulatory response of the tumor cell 
lines to our fibroblast-conditioned medium, one might suggest that such an effect might have 
been masked by the relatively high semm content (5 % FCS) maximally stimulating cell 
proliferation, However, this is contradicted by the fact that MTT tests were performed under 
conditions that still allowed stimulation of growth, e,g., in the presence of higher selUm 
concentrations. 
During the past decade, much effort has been put into the development of systems for 
selUm-free culture of prostatic cells. Indeed, a selUm-free environment is ideal for testing as 
well as identification of regulatory peptides. However, as a consequence of this simplification, 
certain infollnation may be lost, as demonstrated by the results presented in this report. These 
considerations bring to light a crucial dilenuna in oncological research, as stated by Smithers: 
"Reduction gains precision about parts but at each step loses information about the larger 
organization it leaves behind"38. The glandular cells in the prostate receive nutrients, growth-
modulating peptides, trophic nerve factors, and (steroid) hormones that have traversed the 
endothelial cells, stromal cells, extracellular matrix, and the acinar basement membrane. 
Consequently, the stromal compartment has ample opportunity to modify epithelial cell 
microenvironment. It is conceivable that (perhaps unknown) serum-derived factors may very 
well participate in this, for instance, by modifying stromal secretions, as was shown for 
androgen-induced epithelial cell proliferation in the rat prostate', Thus, tests performed in the 
presence of serum or other undefined supplements, such as bovine pituitary extract, will 
provide us with useful information about physiological and pathophysiological processes, and 
are essential to basic oncological research, However, these supplements will eventually hamper 
identification and isolation of the substance(s) of interest. 
So far, TGF-B is the only well-known epithelial cell growth inhibitor that has been 
identified in the prostate",39, Other inhibitory peptides that have been associated with the 
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prostate",40,41 are not likely candidates for elaborating antiproliferative activity in our tests. The 
presence of TGF~B mRNA has been demonstrated in human prostatic tissueD as weB as in rat 
ventral prostate l2 • III vitro studies have implicated TGF-6 as a potent growth inhibitor of 
prostatic epithelial cells, both normal and malignant". Kyprianou and Isaacs l ' showed a 40-
fold increase of TGF-6 mRNAs four days after castration. Androgen administration to four-day 
castrated rats led to a marked decrease in TGF-6 mRNA, to a level comparable to its 
constitutive expression obtained in intact control animals, showing that expression of TGF~B is 
under negative androgenic regulation, In vitro and in vivo experiments showed TGF-B to 
induce programmed cell death of rat ventral prostate glandular cells". Since these studies were 
performed on whole tissue homogenates, no conclusions regarding the source of TGF-B can be 
drawn from these tests. However, prostatic carcinoma cells have been shown to secrete TGF-
639, while the secretion of TGF-B by fibroblasts from other organs is also well documented". 
The work presented here shows that prostatic stroma is also capable of secreting negative 
mediators of epithelial cell growth. Since castration-induced cell death mainly takes place in 
the epithelial compartment, and the ratio of epithelial to stromal cells changes in favor of the 
stromal part, it is tempting to assume that the increase in TGF-B mRNA expression, an active 
process, takes place in the less affected cell type. Definitive answers however, can only be 
expected from studies using ill situ hybridization techniques with TGF-fi-specific probes. 
From this point of view it would be very attractive to explain excessive (Le., 
neoplastic) growth by a failure in this system which may normally regulate prostatic size. It 
could, for instance, be caused by a mutation in the epithelium, rendering it insensitive to these 
factors4-t. Recently, elevated levels of TGF~B immunoreactivity have been associated with 
prostate cancer45 . These observations may reflect insensitivity of cancer cells, possibly 
associated with a resulting failure in the negative feedback loop that controls its production and 
secretion by the stroma. 
In sununary, the data presented here demonstrate that prostatic stromal cells produce 
an epithelial cell growth-inhibiting activity that may share some properties with TGF-B. 
However, especially the results regarding the organ-specific production and action appear to 
distinguish this putative factor from the TGF betas, and strengthen the importance of our 
findings. It would be very interesting to investigate whether this factor is the major 'brake' on 
the prostate, controlling epithelial proliferation and thus prostatic size. Further efforts will be 
made to unravel the identity of this prostatic stroma-derived growth inllibitor. Studies are 
already in progress about the relationship of this factor(s) to the type 6 Transforming Growth 
Factors mentioned above. 
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Abstract 
The paracrine influence of prostatic stroma on the proliferation of prostatic epithelial 
cells was investigated. Stromal cells from the human prostate were previously shown to inhibit 
anchorage-dependent as well as anchorage-independent growth of the prostatic tumor epithelial 
cell lines PC-3 and LNCaP. Anti-proliferative activity, mediated by a diffusible factor in the 
stromal cell conditioned mediulll, was found to be produced specifically by prostatic stromal 
cells. In the present study the characteristics of this factor were examined. It is demonstrated 
that prostate stroma-derived inhibiting factor is an acid- and heat-labile, dithiothreitol-sensitive 
protein. Although some similarities with type beta transfOlming growth factor (TGF-B)-Iike 
inhibitors are apparent, evidence is presented that the factor is not identical to TGF-B or to the 
TGF-B-Iike factors activin and inhibin. Absence of TGF-B activity was shown by the lack of 
inhibitory response of the TGF-B-sensitive mink lung cell line CCL-64 to prostate stromal cell 
conditioned medium and to concentrated partially purified preparations of the inhibitor. 
Furthermore, neutralizing antibodies against TGF-Bl or TGF-B2 did not cause a decline in the 
level of PC-3 growth inhibition caused by partially purified inhibitor. Using Northern blot 
analyses, we excluded the involvement of inhibin or activin. It is concluded that the prostate 
stroma-derived factor may be a novel growth inhibitor different from any of the currently 
described inhibiting factors. 
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Introduction 
Control of cellular proliferation in the prostate involves a complex interaction of 
different cell types with soluble peptide growth factors, (steroid) hormones and constituents of 
the extracellular matrix. It is likely that the array of peptide factors which playa role in the 
regulation of cell proliferation and differentiation affects these processes through both positive 
and negative control mechanisms. The direct importance of embryonic mesenchyme as a 
mediator of the androgen-induced prostatic ductal morphogenesis, epithelial growth, secretory 
cyto-differentiation and function has been demonstrated convincinglyl. Subsequently, it was 
shown that these interactions may have retained their integral role in the adult prostate1,2. It is 
an intriguing observation that, upon maturation, accessory sexual organs reach a typical size 
and weight which is characteristic for that particular organl. Likewise, administration of 
testosterone to androgen-deprived rats restores the size of the prostate to its nomIaI 
precastration level without inducing overgrowth, even after prolonged administrationl. At that 
stage, epithelial cell proliferation is low and in balance with cell death3• Several investigators 
have been searching for the molecular basis of this homeostatic constraint mechanism that 
curtails further increase in cell number once the gland has reached its predetermined size. 
So far, TGF·fi is the only well·known epithelial cell growth inhibitor that has been 
identified in the prostate4,5, Its presence in prostatic tissue has been demonstrated by Northern 
blot analyses6,7, and elevated levels of TGF-13 have recently been associated with prostate 
cancer8, in vitro studies have implicated TGF-fi as a potent inhibitor of prostatic epithelial 
cells, both normal and malignant9-11 • As these cells were shown to secrete TGF-fi 
themselves12 ,lJ, an autocrine mode of action is suggested, ill vivo, TGF-fi has been shown to 
act mainly on the rate of prostatic glandular cell death, while its expression appeared to he 
under negative androgenic regulationl4 . Since these determinations were performed on whole 
tissue homogenates, it is still not clear whether TGF·fi is produced by the stroma or the 
epithelium, A recent immunohistochemical study15 demonstrated immunoreactivity to TGF-J31 
antibodies in epithelial and mesenchymal cells, but unfortunately this kind of experiment does 
not reveal the site of synthesis of the proteins. However, the observation that rat and human 
prostatic epithelial cells grown in vitro can proliferate in serum-free medium without the 
presence of androgens l 6-18, while androgen ablation in vit'O induces a marked regression of the 
glandular epithelium), indicates a major role for the stroma in the negative control of epithelial 
cell proliferation. A number of investigators have studied stromal-epithelial interactions in the 
prostate ill vitro, but their reports mainly focused on the mitogenic influence of the 8trol1111]<)·23. 
No further reports from other groups have been published on stromally derived epithelial cell 
growth inhibitors in the adult prostate. Remarkably, all studies demonstrating stromal 
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stimulation of prostatic epithelial cell growth were perfOlmed under semm-free conditions, 
However, Kirk ef ai, showed an inhibition of PC-3 cell growth by lung fibroblasts, using a 
serum-dependent soft agar assay24. Using a similar assay, we previously observed inhibition of 
the clonal growth of prostatic carcinoma cell lines PC-3 (hormone independent) and LNCaP 
(hormone responsive) by cocultured prostatic stromal cells", Rowley reported growth 
inhibition of a bladder carcinoma cell line by medium conditioned by urogenital sinus explants 
in the presence of 5% FCS and 5% (synthetic) Nu-medium", Later, it was shown that 
antiproliferative activity was produced by a fibroblastoid cell strain probably derived from 
urogenital sinus mesenchyme27. Although cells were shown to express urogenital sinus-derived 
inhibitory factor (UGIF) activity for up to 5-7 days in unsupplemented Dulbecco's Modified 
Eagle Medium (DMEM, changed daily), cultures failed to survive under these unphysiological 
conditions. The presence of the UGIF was tested in a serum-containing assay. Using 
physicochemical, biological, and immunological methods UGIF was demonstrated to differ 
from known growth inhibiting factors including TGF-fi, Using the same bioassay, however, no 
activity could be found in chemically defined medium developed for long-term culture that lVas 
conditioned in exactly the same manner. Only addition of steroid hormone caused the 
fibroblastoid cells to produce inhibiting activity that at the end was identified as being caused 
by activated TGF-fi and not by UGIF28 , Although a semm-free enviromnent is ideal for testing 
as well as identification of regulatory peptides, certain information may be lost, as suggested 
by the findings reported by Kirk", RoWley", and the results presented here, The prostatic 
stromal cell derived antiproliferative activity we found was mediated by a diffusible factor 
present in serum-containing conditioned medium (eM) of stromal cells from neoplastic lesions 
of (adult) prostates",29,lO, In the present report we show that this factor is different from TGF-
fl, its related peptides inhibin and activin, and from other inhibitors previously described, 
Awaiting further identification, we provisionally and operationally refer to this putative 
inhibiting factor as tlprostate-derived Epithelium Inhibiting Factor ll : p-EIF. 
Materials and methods 
Stromal cell cullUl'es 
Surgically obtained tissue specimens from histologically proven benign prostatic 
hyperplasia (BPH) and prostatic carcinoma (PC) were cut into pieces (approximately 1 nun x 2 
mm), and placed in 35 nun petri dishes (Nunc) containing 1.5 ml basal medium: Earle's 
Minimum Essential Medium (Gibco Europe, Brecta, The Netherlands) supplemented with 10% 
FCS (Biological Industries, Beth Haemak, Israel), 2 Mm glutamine, penicillin and 
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streptomycin (all from Gibco). Cultures were maintained in a humidified incubator at 37'C in 
5 % CO,lair. Medium was replaced twice a week. The initial halo of epithelial cells grown 
from these explant cultures became overgrown with fibroblast-like cells within several weeks. 
Subsequently, cells were detached by trypsinization (0.05% trypsin in 0.02% EDTA)(Gibco, 
Europe) and split in a 1:3 ratio every 2-3 weeks. In order to minimize the number of epithelial 
cells in our cultures we used only prostatic stromal cells of passage number 4-9 in this study. 
Using the monoclonal antibody NCL-5D3 (Organon, Oss, The Netherlands) reacting with 
Keratin 8, 18, and 19, we found that the number of positive cells in these cultures (BPH as 
well as PC) never exceeded 5 %, indicating that nearly all cells were of nonepithelial origin)!. 
Cell lines 
The prostatic carcinoma cell line PC-3, obtained from Flow Laboratories (Irvine, UK) 
and maintained in basal medium, was used between passage numbers 35 and 45. LNCaP-FGC 
cells (used at passage numbers 65-70), originally made available to us by Dr. 1. Horoszewicz 
(Buffalo, NY), were cultured in RPMI 1640 (Gibco Europe) supplemented with 10% FCS, 
glutamine and antibiotics. The Mink lung cell line MLCCL 64" was obtained from the NIH 
(Frederick, MO, USA) and cultured in DMEM-high glucose (Gibco Europe) supplemented 
with 7.5% FCS, and antibiotics. All cultures were shown to be free of mycoplasma 
contamination by staining with Bisbenzimide (Hoechst dye 33258) obtained from Sigma (St 
Louis, MO, USA). 
Collection of conditioned medium 
Prostatic stromal cell conditioned medium (~ 0,2 mllcm') was collected twice a week 
from confluent monolayers (approximately 60-100.10' cells/cm'). After centrifugation (6,000 
g; 20 min; 4 'C), CM was stored at -20'C until further use. 
Concentration and pattial purification 
CM of different passages was pooled and fractionated by ammonium sulfate 
precipitation. This was perfOlmed through a stepwise increase in the level of saturation by 
adding solid ammonium sulfate (Sigma) to the medium at O'C under continuous stirring''. At 
every 10% rise the solution was centrifuged (10,000 g; 4 'C; 20 min) and the pellet dissolved 
in PBS (Gibco). Samples from supernatant and pellet were extensively dialyzed (Spectrapor 3-
cutoff: 3500 Dalton; Spectmm Medical Ind., Los Angeles, CA, USA) at 4 'C against PBS and 
MEM, successively, and stored at -20'C after sterilization tlu'ough a 0.45 lun membrane 
(Schleicher & Schuell, 's-Hertogenbosch, The Netherlands). Osmolarity was checked to be 275 
- 325 mOsm, using a Roebling osmometer (Vogel, Giessen, Gennany). Using this 'first-step' 
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purification procedure, 75% of contaminating protein could be discarded30 . 
Physicochemical characterization 
Concentrated and partially purified CM was diluted with PBS to a protein concentration 
of 2 mglml. Trypsin sensitivity was tested by incubation with trypsin (T 8003, Sigma) at a 
concentration of 100 ~glml, for 2 hours at 37'C, followed by the addition of soybean trypsin 
inhibitor (STl) (T 9003, Sigma) at a final concentration of 200 ~glml. As a control, equal 
amounts of trypsin and STI were pre-incubated in PBS for 30 minutes at 20'C, and 
subsequently incubated with the samples for an additional 2 hours at 37°C. 
The reducing agent, dithiothreitol (DTT) (Sigma) was added to each sample at a final 
concentration of 130 Mm. Incubation was performed on a rocker platform for 60 minutes at 
20°C. Control samples were incubated without DTT. 
Acid treatment was performed by acidifying samples to Ph 1.5 with 2 M hydrochloric acid for 
1 h at 20'C, then neutralizing by 2 M sodium hydroxide. Control samples were adjusted to the 
same volume as test samples, using 2 M sodium chloride. 
Heat sensitivity was tested in the presence of 100 Mm Hepes, at 56°C for 30 minutes, or at 
100°C for 3 minutes. Samples were incubated in closed glass tubes in a rocking water bath. 
Controls for all tests mentioned above were obtained by similar treatment of basal medium 
(diluted to a protein concentration of 2 mg/ml). After incubation, all samples were 
subsequently dialyzed at 4 'C against PBS, and MEM, and sterilized by filtration over a 0.45 
~m pore membrane. For determination of growth inhibition (MTT-test), 180 1'1 of sample and 
20 1'1 of FCS were added at day O. 
Stability at a range of temperatures was tested by heating aliquots of CM for 5 minutes at 
indicated temperatures. In order to keep the pH at the same level throughout the incubation, 
Hepes was added to a concentration of 100 mM. As a control, basal medium and semm-free 
basal medium were treated likewise. Samples were subsequently dialyzed against PBS and 
MEM and the inhibition of cell growth was tested after sterile filtration, using the MTT-test or 
the [JH)-thymidine incorporation assay. 
Neutralization tests 
TGF-fil from human platelets and TGF-B-l neutralizing polyclonal antibodies raised in 
rabbits were prepared at the Hubrecht laboratory, Utrecht, The Netherlands". Porcine platelet 
TGF-B2 was obtained from Sandoz (Basle, Switzerland), while TGF-B2 specific (neutralizing) 
antibodies, also from rabbit, were purchased from R&D Systems Inc. (Minneapolis, MN, 
USA). Concentrated, semipurified inhibitor was diluted to 1 mglml, preincubated with 
antibody (30 I'glml) for 1 h at 37'C, and subsequently added to wells containing PC-3 cells 
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(MTT test). Controls were obtained by pre-incubation with non-immune serum IgG. Activity 
of immune selUm IgG was tested by incubation of TGF-fil (10 ngiml in MEM 0.1 % BSA) 
with equal amounts of antibody. Tests with TGF-fi2 specific antibodies were perfOlmed with 
80 Itgiml antibody, and for controls 20 ngiml TGF-fi2 was used. Optimal amounts of antibody 
(saturable activity) were determined by incubating inhibitor with different amounts of antibody. 
Protein determination 
Protein concentrations were measured with the Bio-Rad Protein Assay Kit (Bio-Rad 
Labs, Veenendaal, The Netherlands). A 1:I-mixture of the albumin and globulin solutions was 
used as a standard. 
Growth inhibition assays 
Inhibition of cell growth was determined by means of a colorimetric assay based on the 
reduction of a tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MIT), to a colored formazan product (maximum absorption at 560 nm) by mitochondrial 
enzymes present only in living, metabolically active cells". Cells were harvested by 
trypsinization, resuspended in fresh culture medium, and plated in a volume of 0.1 Illl per well 
in 96-well microtiter plates (Costar). Inoculum: PC-3, 2,000 per well; LNCaP, 5,000 per well; 
MLCCL-64, 1,500 per well. The next day (day 0), 0.1 ml of sample was added, giving a 50% 
dilution of the sample. At day 3, 30 1'1 of a 5 mgiml solution of MTT (Sigma) in PBS was 
added to each well. After a 4 h incubation at 37°C in 5% CO2/air, the medium was carefully 
sucked off and the purple dye was dissolved in 0.1 ml DMSO (Merck, Darmstadt, Gemlany). 
Plates were placed on a plate shaker for 5 minutes, and the absorbance at 560 nm was read 
using a Flow Titertek Multiskan plate reader. Unless otherwise stated, eight replicate wells 
were used for each sample. Wells containing medium but no cells served as blanks. Results are 
expressed as percentage of maximal growth from day 0, obtained in fresh basal medium. To 
determine the number of cells at this point, one extra plate was used and (16 wells) measured 
at day O. 
['H)-Thymidine incorporation was measured using 5,000 MLCCL-64 cells per well in 
24-well plates (Nunc). The Mink lung carcinoma cell line CCL-64 is known to be very 
sensitive to TGF betas IJ .J6 Cells were plated on day 1 in 1 ml DMEM (Gibco) supplemented 
as described. After 4 h, 0.1 ml of sample was added. At day 3, 0.5 I'Ci ['H)-thymidine 
(Amersham, UK) in 0.1 ml Ham's F12 medium was added to each well and plates were 
incubated for another 16 h. Monolayers were washed 4 times with PBS, then fixed in methanol 
for 15 min at room temperature and dried in air. Cells were then dissolved in 1 ml 1M NaOH 
(30 min, 37°C), transferred to a scintillation vial and radioactivity was counted. 
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Northern blot analyses 
After removal of culture medium, stromal cells were frozen in solid CO2/ethanol, and 
stored at -SOOC. Total RNA was isolated using an acid guanidinium thiocyanate-phenol-
chlorofonn extraction procedure". Of each sample, 40 "g of total RNA was denatured in 
formamide/formaldehyde at 55'C for 15 min, before electrophoresis on denaturing 1 % 
agarose/formaldehyde gels. After electrophoresis, RNA was blotted on Hybond N + 
Amersham, UK) by diffusion. Filters were baked for 2 h at SO'C, and subsequently 
prehybridized for 2 h at 42'C in a hybridization solution containing 50% formamide, 9% w/v 
dextran sulphate, lOx Denhardt's [Ix Denhard!,s contains 0.02% w/v/ Ficoll, 0.02% w/v 
polyvinyl pyrrolidone, 0.02% w/v BSA], 5x SSC (Ix SSC contains 0.15 M NaC!, 0.Dl5 M 
sodium citrate, pH 7.0), 10 mM sodium phosphate (pH 6.S), and 100 "g/ml denatured salmon 
sperm DNA. Probes for hybridization were labelled with 32p by random oligonucleotide 
labelling", denatured in boiling water for 5 min and added directly to the hybridization 
solution. Following 4S h of hybridization at 42'C, filters were washed to a final stringency of 
O.lx SSC, 0.1 % SDS, 50'C. Filters were exposed to Amersham Hyperfilm-MP (Amersham, 
UK) at -70ce for various lengths of time, using an intensifying screen. Probes used were 
described by Esch39 and Derynck". As a control for equal amounts of RNA, a hamster actin 
eDNA probe was used. 
Statistical analysis 
The statistical significance of differences between individual treatment groups was 
calculated using Student's t test. Differences were considered statistically significant if the two-
tailed P value was smaller than 0.05. 
Figure 1. Inhibition of PC-3 cell 
growth by prostatic stromal cell CM. 
The Y-axis gives the absorbance at 560 
run as determined by the MTT test (see 
Material and Methods). All samples 
were dialyzed against basal medium 
without FeS. BM, basal medium; CM, 
Conditioned medium. Error bars, SD. 
104 
A 56011111 
1.2 
1.0 
0.8 
0.6 
0.4 
0.2 <,.-:., 
0.0 
o 
8M 
PBS 
OM 
2 3 4 
Time (days) 
Stroma derived inhibition lIot mediated by TGF-fJ 
Results 
Effect of prostatic stromal cell CM and partially purified inhibitor 011 the growth of 
prostatic tumor epithelial cells 
We previously reported the inhibition of anchorage-independent growth of the 
hormone-insensitive prostatic carcinoma cell line PC-3 as well as the honnone-responsive 
prostatic carcinoma cell line LNCaP, by cocultured prostatic stromal cells". Figure 1 shows 
that CM from prostatic stromal cells was capable of iohibiting the growth of PC-3 cells in 
monolayer cultures up to approximately 50%. Growth in PBS was significantly better than that 
found in dialyzed CM, indicating that the iohibition was not due to depletion of nutrients or of 
growth promoting factors. 
Concentration and partial purification of CM resulted in a potent solution reaching inhibition 
levels up to 80-90% at protein concentrations less than 5 mg/m!. In a comparative experiment, 
BSA was shown to interfere with cell growth only at higher concentrations, demonstrating that 
the observed inhibition of semi-purified inhibitor was not merely due to a high protein content. 
As a control, basal medium and CM from skin fibroblasts were fractionated in a similar way. 
No inhibiting activity was found in these preparations. As can be seen in the dilution curves in 
Figure 2, LNCaP cells are almost equally sensitive to the antiproliferative activity as PC-3 
cells. Preliminary studies on primary cultures of BPH and prostatic carcinoma epithelium 
showed these cells to be responsive too. 
A· 2.5 mg/ml c: 0.156 mg/ml 
B: 0.625 mg/ml D· 0.039 mg/mt 
120 E: 0.010 mg/ml 
100 T T 
T 
~ 80 T 
.c 60 
- ,I, ~ T 0 
Figure 2. Serial dilutions of partially ~ (!) 40 
purified inhibitor on human prostatic 
carcinoma cell lines PC-3 and LNCaP, 
20 A B C 0 E A B C 0 E 
as determined by means of the MTT-
test. Growth is given as percentage of 
0 growth obtained in fresh basal medium. 
Error bars, SD. PC-3 LNCaP 
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Biochemical chal'acterization 
The inhibitory activity of partially purified p-EIF preparatioI15 was tested under 
different conditions in an attempt to elucidate the nature of the putative inhibitor. The fact that 
the inhibitor could be precipitated by ammonium sulfate already suggested that a protein is 
involved. This idea was supported by the observation that trypsin digestion resulted in a 
statistically significant reduction in inhibitory activity (Figure 3A). Treatment with DTT 
resulted in a complete disappearance of activity (Figure 3B), demonstrating the requirement of 
S-S bridges for biological activity. Acid treatment of partially purified inhibitor significantly 
reduced the inhibiting activity (Figure 3C). Surprisingly, treatment of basal medium resulted 
in the generation of inhibiting activity, which may explain the observation that inactivation of 
the stromal cell-derived inhibitor did not restore growth to 100%, although inactivation of 
growth-promoting substances might as well have contributed to this effect. Figure 3D shows 
that treatment of the concentrated fraction of inhibitor at 56°C for 30 minutes resulted in a 
small, but statistically significant, decrease in anti proliferative activity. This observation 
suggested p-EIF to be heat labile. However, heating at 100"C restored the inhibiting activity to 
Figure 3. Physicochemical 
characterization of prostatic stromal 
cell derived inhibitor partially 
purified by ammonium sulfate 
precipitation. Inhibitor (P) and basal 
medium (BM) were treated with A: 
trypsin (T); B: dithiothreitol (DTT); 
C: acid (pH 1.5); D: Heat (56"C and 
100°C). C (control), initial solution 
of inhibitor or basal medium; TIS, 
Trypsin preincubated with soybean 
trypsin inhibitor (for details see 
Materials an Methods); Bars, SD; *, 
significantly different from control. 
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levels found before treatment, while similar effects were seen after heating basal medium. In 
order to look at this aspect more carefully, we performed similar experiments on CM, using a 
wider range of temperatures. The increasing levels of inhibition generated in basal (semm-
containing) medium by treatment at higher temperatures are clearly demonstrated (Figure 4A). 
However, a tendency of the stromal cell inhibitor to lose its inhibiting capacity (observed after 
heating at 56°e and 70°C) was noted. 
Growth {%) A B 
-D- 8M 
o M-
-0- eM 
Figure 4. Induction of inhibitory activity by heat exposure. Samples of CM, basal medium (BM) 
including 10% FeS, and basal medium without serum (M-), were subjected to the temperatures 
indicated. Activity of samples was tested A) on PC-3 cells using the MTT test (lines); and n, in the 
TGF-fi assay on MLCCL-64 cells measuring[JH]-thymidine incorporation (bars), showing activation of 
latent TGF-fi after heating at higher temperatures. For comparison, the curve for basal medium tested 
on PC-3 cells is shown again in graph B. Growth is given as the percentage of control cultures grown 
in fresh basal medium. Levels of significance were calculated in relation to the untreated CM; *, 
P';;O.05; **, P';;O.OI; Bars (graph A), SD. 
Northel'll blot analysis 
To explore the possibility that TGF-B or TGF-B-like substances were the active 
component in stromal cell-derived medium, Northern blot analyses were used to examine the 
possible expression of mRNAs coding for these compounds in stromal cells. Confluent cultures 
of stromal cells from BPH, Wilms' tumor and normal kidney tissue were used. TGF-BI 
mRNA was shown to be present in all four cultures investigated (Figure 5). However, since 
stromal cell CM from Wilms' tumor and normal kidney tissue did not inhibit PC-3 cell 
growth", this does not necessarily imply that sufficient amounts of (active) TGF-B are secreted 
into the medium. 
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We also examined the involvement of activin and inhibin in cultured prostatic stromal 
cells. As shown in Figure 5, no fi·AIB chain or ",·chain mRNAs were detected in prostate 
derived stromal cell cultures, indicating that neither activin nor inhibin was synthesized in 
these cells. Hybridization occurred only with the probe for the B·A chain and was restricted to 
cultures derived from normal kidney tissue. The presence of fi·A mRNA in human kidney 
fibroblasts, however, has not been reported before41 , 
1 2 3 4 C 
BA [5.6 kb] 
138 [4.2 kb] 
[3.5 kb] 
'I'GF-B[2.5 kb] 
It C\! [1.6 kb] 
I •• Actin[2.2 kb] 
Figul'e 5. Northern blot analysis of total RNA from stromal cell cultures derived from Wilms' tumor 
(lane 1), tissues from two different BPH patients (lane 2 and 4), and normal kidney tissue (lane 3). C: 
Sertoli celis, known to express inhibin mRNAs, were used as a control. fiA, fiB: activinlillhibin 
subunits; a: inhibin a-subunit. 
Bioassay \Ising MLCCL-64 cells fol' detection of TGF-fl activity 
To test the production of active TGF·fi by prostate derived stromal cell cultures, we 
used a bioassay with the TGF·fi·sensitive miok lung carcinoma cell line MLCCL·64. For 
comparison, the inhibition of PC·3 cell growth by TGF·fi and partially purified inhibitor was 
also determined. Both TGF·Bl and TGF·fi2 were found to inllibit PC·3 cell growth (Figure 
6A). The concentrated solution of inllibitor had to be diluted 10 times to calise an inhibition 
similar to that of 5 ng/ml TGF·B. As might be expected, TGF·BI and TGF·B2 had a stronger 
antiproliferative effect on MLCCL·64 cells than on PC·3 cells (Figure 6B). However, no 
significant inhibition of MLCCL·64 cell growth was observed with CM or with serial dilutions 
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of the partially purified inhibitor. These data demonstrate that CM-mediated inhibition of PC-3 
cell growth was not caused by TGF-6. Those findings were confirmed by the highly sensitive 
[-'H)-thymidine incorporation assay on MLCCL-64 cells that appeared to be slightly stimulated 
by fresh frozen CM as well as by partially purified p-EIF (not shown). However, after 
prolonged storage (more than 2 months) CM tended to gain some inhibitory activity on both 
cell types compared with fresh basal medium, probably as a result of activation of latent TGF-
beta. 
Using this [3H)-thymidine incorporation assay on MLCCL-64 cells increasing amounts 
of active TGF-6 were also detected in samples from basal medium and from CM, after heating 
(Figure 4B). 
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Figure 6. Serial dilutions of TGP-fil (-0-) TGF-fi2 (-+-) and partially purified inhibitor (-0-) on A) 
PC-3 cells, and B) MLCCL-64 cells, tested in the MTT-assay. TGF-fis were diluted in MEM 
containing 0,1 % BSA. The serial (2-fold) dilutions of inhibitor (Pellet 40-50%) were prepared in 
MEM, Highest concentration: l250 I-!g/ml. Results are given as percentage of growth of control 
cultures grown in fresh basal mediuIll, Bars, SD, 
Effect of TGF-B neutralizing antibodies 
In order to confirm the absence of active TGF-6, we performed MTT-tests on PC-3 
cells using neutralizing antibodies against TGF-61 and TGF-62. As shown in Figure 7 A, pre-
incubation of TGF-BI with polyclonal antibodies raised against purified TGF-61, neutralized its 
effect completely. Those antibodies,however, did not cause a significant decline in the level of 
inhibition induced by partially purified p-EIF. Tests with TGF-62-specific antibodies gave 
essentially the same results (Figure 7B). These findings, again, demonstrated that the putative 
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inhibitor present in the CM is different from TGF-B. Since PC-3 cells are known to secrete 
predominantly TGF-B2 in their CM!l, we were also interested in the influence of TGF-02 
antibodies on the growth of PC-3 cells themselves. Figure 7B shows that these antibodies did 
not improve the growth of the PC-3, indicating that there was no active 'autocrine' TGF-02 
present that could be recognized by the antibodies. 
Growth 1%1 A B 120 
100 
80 T 
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40 In 20 
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Figure 7. Effect of TGF-B neutralizing antibodies on growth inhibition induced by prostatic stromal 
cell-derived inhibitor. A) TGF-JH antibodies. B) TGF-B2 antibodies, Solutions of immune serum (I), 
nonimmune serum (N), TGF-JH (T in graph A) and TGF-B2 (T in graph B) were prepared in MEM 
containing 0.1 % BSA (LVl). Preparations of partially purified inhibitor (P) were diluted in the same 
solution. TGF-B and stromal cell inhibitor were mixed with equal amounts of antibody and all samples 
were preincubated for I h at 37°C before they added to the test. Bars, SD (1/ = 6). *, T+ 1 is 
significantly different from T and not different from I; **, P+ I is not significantly different from P 
and different from I. 
Discussion 
Following the observation that epithelium loses its growth capacity when separated 
from the stroma42 , it has become increasingly clear that both autocrine and paracrine factors 
produced by epithelial and stromal cells play an important role in the local control of prostatic 
growth, It has been demonstrated that urogenital sinus mesenchyme plays a major role in the 
(androgen-induced) development of the gland!; subsequently it was shown that these 
interactions may have retained their integral role in the adult prostate1.2.43, These observations 
indicated that the development of cancer and other disease states is likely to involve a loss of 
coordination or other alterations in such interactions, McNeal has suggested the reversion of 
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prostatic stroma to an 'embryological state' inducing inappropriate epithelial proliferation in 
benign prostatic hyperplasia". Tenniswood hypothesized the existence of two growth-
stimulating factors and one growth inhibitor, produced in stroma and epithelium, that control 
growth and differentiation. He also suggested that the development of BPH may be caused by 
continuously elevated expression of one or more of these factors4S , Indeed, several epithelial 
cell growth-promoting peptides have been identified in the prostate and in prostate-derived 
epithelial cell cultures"''', and some of these have been positively identified as being produced 
(also) by stromal cells, suggesting a role in stromal-epithelial interactions21.23 ,48, 
The fact, however, that prolonged androgen administration to castrated animals does 
not induce the gland to grow beyond its predetermined size49 , together with the observation 
that withdrawal of androgens decreases epithelial cell number only in the ill vivo situation 
where stroma is presentJ,16, suggests a role for stromally derived epithelial cell growth 
inhibitors. To date, the only well-studied epithelial cell growth inhibitor identified in the 
prostate is TGF-134, The transforming growth factor 13 family includes a group of closely 
homologous proteins50• Three distinct molecular forms, designated TGF-nl, TGF-B2 and TGF-
63, have been identified in manlInals5, Most cells, including stromal cells, secrete TGF-fi as a 
latent complex which can be activated by treatment with heat, acid or proteases such as 
piasmin28 ,51, Also, commercially available sera have been shown to contain latent TGF_1351, The 
expression and activation appears to be influenced by steroid hormones7,!9, as was shown also 
for urogenital sinus mesenchyme28 , The expression of TGF-B mRNA in human prostatic tissue 
[TGF-nl and n2J6 as well as in rat ventral prostate [TGF-nIJ' has been demonstrated by 
Northern blot analyses, Recent immunohistochemical studies of diseased human prostates 
demonstrated TGP-131 immunoreactivity in both epithelial and mesenchymal celJs15, In vitro 
studies with TGF-n I have shown that this factor inhibits proliferation of prostatic carcinoma 
cell lines PC-3, DU 145 and LNCaP IO.I1.", while PC-3 cells were found to secrete latent TGF-
n (predominantly n-2) in the culture medium!'·!'. 
Two other members of the TGF-B family of growth and differentiation factors are 
activin and inhibin50 , Both factors were previously shown to compete for TGF-B binding to 
pituitary tumor cells". Furthermore, TGF-n-like properties of activin in developmental biology 
were recently demonstrated55 , Both activin and inllibin can interfere with cell growth56,57, and 
inhibin-like proteins were demonstrated in seminal plasma and prostate tissue58 , 
Using a two layer soft-agar system, we previously observed an inllibition of the clonal 
growth of prostatic carcinoma cell lines by prostatic stromal cells. It was shown to be mediated 
by a diffusible factor present in the CM",JO which we referred to as p-EIF". In the present 
work we investigated the possibility that p-EIF is identical to one of the well-know epithelial 
growth inllibitors mentioned above. Since TGF-B mRNAs were expressed in our stromal cell 
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cultures (Figure 5) active TGF-B could have been produced (among latent TGF-B) by the 
stromal cells". On the other hand, the active fraction of inhibitor might consist of 'fibroblast-
activated' latent TGF-B, for instance, present in the serum52 .59 . Our data show that p~EIF has 
several properties in common with TGF-B, including reversibility of inhibition3o.60 and 
sensitivity to trypsin and reducing agents. Elaboration of inhibiting activity under acidic 
conditions (Figure 3C) is known to occur in solutions containing latent TGF-B5!. From the 
observations described above we may conclude that latent TGF-B was derived from the sel1lm 
present during conditioning and/or secreted by the stromal cells themselves. Since activation 
was observed in stability tests perfOlmed on concentrated partially purified inhibitor 
preparations, we have to conclude that latent TGF-B co-precipitated with p-EIF, at 40-50% 
ammonium sulfate saturation. Similar considerations apply to heat treatment (Figure 3D). 
However, the tendency of the inhibitor to lose its inhibiting capacity upon heating (significant 
at 56°C and 70°C), was probably obscured at higher temperatures by the generation of active 
TGF-B from the solution (Figure 4). This observation appeared to discriminate our inhibitor 
from the TGF-B family of growth modulating factors. However, since the sample is not highly 
purified yet, we realize that the possibility of co-precipitation of active inhibitor adhering to 
other denatured products cannot be mled out. Nevertheless, further strong biological and 
immunological evidence was provided demonstrating that p-EIF is different from these 
inhibitors. In particular the observation that the antiproliferative effect of semipurified p-EIF 
was not altered by TGF-fil and TGF-fi2 neutralizing antibodies (Figure 7) mled out the 
presence of active TGF-fil and TGF-fi2 in these preparations. Absence of inhibition of MCF-7 
cells3o, sensitive to all three TGF_Bs61.62, supported this conclusion. In addition, the lack of an 
inhibitory effect on MLCCL-64 cell growth (Figure 6) argued strongly against the action of 
TGF-fil, fi2 or B361. 
Recently, growth inhibition of a bladder carcinoma cell line as well as PC-3 cells by 
semm-containing medium conditioned by a fibroblastoid cell strain subcultured from urogenital 
sinuswas reported16.". Physicochemical properties of the reported factor (UGIF) suggest that it 
is different from that found in the present study. However, it should be kept in mind that in 
both cases tests were perfOlmed on crude preparations limiting the value of these observations. 
Limonti reported the antiproliferative effect of luteinizing hormone-releasing hormone (LHRH) 
agonists on LNCaP cells. Specific binding sites were demonstrated, while receptor as well as 
peptide levels were thought to be negatively regulated by androgens". However, since stromal 
cell-derived inhibitory activity was not lost upon dialysis (cutoff 3.5 kD), these peptides can be 
ruled out as candidates for the reported inhibitory activity on the basis of their molecular size. 
Interferons (IFN) have also been shown to inhibit growth of prostatic epithelial cells"'·65, and, 
among other cell types, fibroblasts have been recognized as a rich source of interferon 
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(arbitrarily called IFN-B)". We believe, however, this is not a likely candidate either, for two 
reasons. First, untreated fibroblasts produce subeffective concentrations of IFN, and only 
treatment with 'inducers' (e.g., vhus infection or double-stranded RNA chains) leads to the 
secretion of detectable amounts of IFN-B in the CM. Second, LNCaP cells were shown not to 
be inhibited by IFN-B", while we demonstrated inllibition of anchorage-dependent and 
anchorage-independent growth of LNCaP cells by prostatic stromal cell CM. 
In conclusion, the data presented in this paper demonstrate that adult prostate derived 
stromal cells cultured from neoplastic lesions, produce a unique factor, tentatively called 
'prostate-derived Epithelium Inllibiting Factor'(p-EIF). On the basis of its spectrum of 
biological activity as well as its physicochemical and immunological properties, p-ElF can be 
discriminated from previously described growth inhibitors, including the TGF-B-related 
proteins inhibin and activin50, and from interferon beta". The organ-specific production and the 
lack of inhibition on all non-prostatic epithelial cell lines tested, emphasize the hnpOl"tance of 
this inhibitorJO. It would be very interesting to investigate whether this factor is the major 
'brake' on the prostate, controlling epithelial cell proliferation and thus prostatic size. Several 
aspects concerning the production of p-EIF are still under investigation. Preliminary data 
suggest that senllll-derived factors are required for optimal production andlor secretion. 
Preliminary results did not show significant effects of steroids (testosterone, 
dihydrotestosterone, or estradiol) in this respect however. Further knowledge of the factors 
influencing its production will facilitate purification and characterization. Antibodies raised 
against the purified factor would provide us with an excellent tool for studying its role in 
normal physiology and its possible involvement in the development of neoplasia. 
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7.1. Introduction 
In terms of incidence prostate cancer has surpassed lung cancer as the leading cancer in 
men in the United Statest. A better understanding of the mechanisms which regulate prostatic 
growth in the normal and neoplastic prostate may facilitate the clinical manipulation of 
aberrant prostatic growth, Since the epithelium of the prostatic glandular acini is surrounded by 
a well,developed fibromuscular stroma, cell,to,cell conm1Unication has been implicated in the 
regulation of prostatic growth. 
As reviewed in Chapter 2 of this thesis, paracrine regulation of prostatic growth was 
first suggested by Franks et al,2 after observing a lack of growth capacity of epithelia which 
had been separated from the stroma. Tissue recombination studies using fetal stroma 
(mesenchyme) of the urogenital sinus and (adult) bladder epithelium revealed the appearance of 
prostatic epithelial mOlphogenesis indicating that the epithelial differentiation is based on 
instmctive induction by the stroma rather than on irreversibel commitment of the epithelial 
cells', The growth and thus the size of the 'neo,prostate' was found to be stroma (cell) density' 
dependent4. Tissue recombination studies with testicular feminization and wild type tissues 
have shown that the target of androgen action is the mesenchyme, which in turn mediates the 
growth of adjacent epithelial cells'. It was shown that in adult rat prostate androgens mediate 
the secretion of stromally,derived growth factors which stimulate epithelial proliferations,6, 
Another intriguing observation is that, upon maturation, accessory sexual organs reach 
a typical size and weight which is characteristic for that particular organ3. Likewise, 
administration of testosterone to androgen deprived rats restores the size of the prostate to its 
normal precastration level and no overgrowth is induced even after prolonged administration or 
the use of supraphysiological doses', Indeed. in intact adult rats androgen levels are high while 
prostatic epithelial cell proliferation is low and in balance with cell death', Several 
investigators have been searching for the molecular basis of this homeostatic constraint 
mechanism that curtails further increase in cell number once the gland has reached its normal 
size. The observation, however, that normal rat and human prostatic epithelial cells grown in 
vitro (Le. without stroma) are able to proliferate in selUm~free medium without the presence of 
androgens9-12 , while androgen ablation in the presence of connective tissue induces a marked 
regression of the glandular epithelium', warrants the search for stromally,derived epithelium 
inhibiting factors in the prostate. That stroma not only induces a mitogenic response, but can 
also act as a 'brake' on the epithelium. is suggested by observations made on other organ 
systems, Negative regulators of cell growth have been demonstrated ill other fibroblast 
cultures lJ-15 • Several coculture experiments as well as ill vivo studies showed the controlling 
influence of the stroma on the epithelial compartment, ranging from induction of 
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differentiation16,l7 to tumor cell degeneration18 , Similar experiments carried out on the male 
genital tract fit in with these findings. Rowley and Tindall19 found that diffusible factors 
produced by fetal urogenital sinus decreased the proliferation of bladder carcinoma cells in 
vitro. Recently, Chung et al." showed a marked growth inhibition of a hormone-independent 
rat prostatic tumor cell line (Nb-102-pr) when grafted in combination with urogenital sinus 
mesenchyme, Hayashi and Cunha2l , performing similar experiments on Dunning R3327 rat 
prostate tumor lines, demonstrated a reduction in epithelial cell growth rate and an apparent 
reduction or loss of tumorigenesis of these cells. Indeed, those findings indicate that, in the 
urogenital tract, mesenchymal cells are capable of inhibiting epithelial cell proliferation. 
7.2. Characterization of explant cultures of human prostatic stromal cells 
Detailed studies of stromal-epithelial interactions are facilitated by the availability of 
separately cultured epithelial and stromal cells, permitting reconstitution and analysis of their 
interactions under defined conditions, There have been several reports concerning primary 
culture of murine prostate epithelial 9 and stromal cells 5,22.24, while less information is 
available on in vitro models derived from human tissue, Although several human prostatic 
carcinoma cell lines have become available during the past decade 25-28, and methods were 
developed for primary culture of epithelial cells from normal and diseased prostates 10,29-32, 
only a few papers have been published about studies using cultured human prostatic stromal 
cells, So far, no studies have been conducted regarding the characterization of human prostatic 
stromal cells. These cells were tentatively designated as fibroblasts, a nomenclature mainly 
based on cell morphology. Since we planned to perform ill vitro experiments on stromal-
epithelial interactions using human prostatic 'fibroblasts' as stromal cells, we decided to 
analyze these cultures first. 
Stromal cell cultures derived from prostate cancer tissue and from BPH nodules were 
characterized immunocytochemically using antibodies against the intermediate-sized filament 
proteins keratin, vimentin, and desmin, and antibodies against smooth muscle actin 
microfilaments33 .34 As shown in Chapter 3, the stromal cell populations derived from BPH and 
prostatic carcinoma differed with regard to their differentiation markers. Whereas BPH-derived 
stromal cell cultures predominantly consisted of fibroblastic cells, stromal cells derived from 
malignant lesions in addition showed smooth muscle differentiation (myofibroblast). The 
outgrowth of different cell populations under similar culture conditions is indicative of a 
remarkable divergence in the stromal-epithelial relationship between these two pathological 
conditions with clinically different behavior; this may provide an excellent tool for studying 
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these processes. However, as the difference in phenotypes between BPH and carcinoma-
derived cultures may gradually fade at subculture, it should be recommended to cany out 
(coculture) experiments with stromal cells from the earliest passage possible. Unfortunately, 
the nature of our experiments did not permit us to use very low passage number cells under all 
circumstances. Since the experiments required large numbers of stromal cells, these cells had 
to undergo several population daub lings before sufficient numbers were obtained; they had to 
be subcultured at least four times. At passage number four, however, the 
immunocytochemically detennined phenotypic difference between 'malignant' and 
'noIUllalignant' stromal cells was lost. This may explain why we have not been able to notice 
any significant differences in inhibitory activity between tests performed on BPH-derived or 
prostatic carcinoma-derived stromal cell CM. Although in coculture experiments (chapter 4) at 
low stromal cell densities a somewhat stronger inhibion was observed using carcinoma derived 
stromal cells, at higher cell numbers no striking differences were observed between the 
maximal levels of inhibition reached by the two stromal cell types. Likewise, besides the 
tendency to obtain a similar phenotype at subculture, the lack of a significant difference in 
level of activity of CM from malignant and nomnalignant stromal cell cultures may as well be 
due to the high cell del15ity needed for production of potent CM. 
7.3. Negative control of epithelial cell proliferation by prostatic stroma 
Initially, the influence of prostatic stromal cells on the growth of the prostatic 
carcinoma cell lines PC-3 (hormone independent) and LNCaP (hormone dependent) was 
examined using a double layer soft agar system which mechanically separates both cell types. 
Clonal growth of both cell lines was inhibited by all prostatic stromal cell strains tested 
irrespective of whether they were derived from malignant or non-malignant prostate tissue. 
Irradiated as well as quiescent stromal cells showed similar effects indicating that the activity 
is not dependent on cell proliferation. Inhibition was shown to be mediated by a diffusible 
product(s) present in the conditioned medium of the stromal cells. Organ specific secretion is 
suggested by the observation that skin fibroblasts were stimulatory in these tests. 
To elucidate this interaction further, we established a number of stromal cell cultures 
from human prostatic carcinomas as well as benign prostatic hyperplasia nodules, and 
investigated the influence of conditioned medium of these cultures on the anchorage-dependent 
growth (monolayer cultures) of different epithelial cell lines from human and murine origin 
(chapter 5). Likewise, several nonprostatic stromal cell cultures were initiated. and their CM 
tested. Using the 'MTT-test', a convenient semi-automated assay, antiproliferative activity was 
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found to be reversible, dose-dependent, and produced specifically by prostatic stromal cells 
and not by stromal cells derived from skin, foreskin, utelUs, kidney, and \Vilms' tumor. 
Inhibition was not species-specific, since the cell lines AT-2.1 and MATLyLu, derived from 
the Dunning rat prostate tumor, were also sensitive, Breast and renal carcinoma cell lines were 
not inhibited, however, suggesting a prostate-specific action. The putative inhibiting factor(s) 
could be concentrated and partially purified by ammonium sulfate precipitation indicating that 
protein structures are involved. This idea was confirmed by the observation that after trypsin 
digestion inhibitory activity was lost. Further physicochemical characterization showed a 
molecular weight> 3.5 lcD, and a sensitivity to reducing agents, indicating that the presence 
of S-S bridges is needed for biological activity. It was also suggested that the putative inhibitor 
may be acid- and heat labile. 
TransfOlming growth factor-B is the only well-known epithelial cell growth inhibitor 
that has been identified in the prostate13·". The presence of TGF-B mRNA has been 
demonstrated in human prostatic tissueJ6 as well as in rat ventral prostate37 , III vitro studies 
have implicated TGF-B as a potent growth inhibitor of prostatic epithelial cells, both normal 
and malignant". Kyprianou and Isaacs" showed a 40-fold increase of TGF-B mRNAs four 
days after castration. Upon androgen administration to four-day castrated rats levels returned 
to precastration values, showing that expression of TGF-B is under negative androgenic 
regulation. [II vitro and ill vivo experiments showed TGF-B to induce programmed cell death of 
rat ventral prostate glandular cells39 , Since these studies were performed on whole tissue 
homogenates, no conclusions regarding the source of TGF-fi can be drawn from these tests, 
However, prostatic carcinoma cells have been shown to secrete TGF-fi in vitro35 , while the 
secretion of TGF-fi by fibroblasts from other organs is also well documented]), Since 
castration-induced cell death exclusively takes place in the epithelial compartment, and the 
ratio of epithelial to stromal cells changes in favor of the stromal part, it is tempting to assume 
that the increase in TGF-B mRNA expression, an active process, takes place in the less 
affected cell type. Moreover, the fragmentation of genomic DNA of the epithelial cells, shown 
to be an early event in programmed cell death", may argue against the possibility that a 40-
fold rise in TGF-B mRNA level on day 4 is caused by transcription of epithelial DNA. 
Defmite answers however, can only be expected from studies using in situ hybridization 
techniques with TGF-B specific probes. 
From this point of view it would be attractive to explain excessive (i.e., neoplastic) 
growth by a failure in the negative control system which may normally regulate prostatic size. 
It could, for instance, be caused by a change in the epithelium, rendering it insensitive to these 
factors41 • Recently, elevated levels of TGF-B immunoreactivity have been associated with 
prostate cancer42 , These observations may reflect insensitivity of cancer cells, possibly 
124 
Summary and concluding remarks 
associated with a resulting failure in the negative feedback loop that controls its production and 
secretion by the stroma. A recent immunohistochemical study'H demonstrated immunoreactivity 
to TGF-fil antibodies in epithelial and mesenchymal cells, but unfortunately this kind of 
experiments also does not reveal the site of synthesis of the proteins. 
At this stage in our research it was conceivable that the stromal cell derived inhibition 
was caused by the action of TGF-B. However, our latest experiments excluded this possibility 
(chapter 6). Although some similarities with type B transforming growth factor-like inhibitors 
were apparent, it was concluded that the factor is not identical to TGF-B or to the TGF-B-like 
factors activin and inhibin for the following reasons. First, using MTT-tests as well as [3H]_ 
thymidine incorporation assays, the absence of TGF-B activity was shown by the lack of 
inhibitory response of the TGF-B-sensitive mink lung cell line CCL-64 to prostate stromal cell 
conditioned medium and to concentrated, partially purified preparations of the inhibitor. 
Furthermore, neutralizing antibodies against TGF-Bl or TGF-B2 did not cause a decline in the 
level of PC-3 growth inhibition caused by partially purified inhibitor. Northern blot analyses 
excluded the involvement of inhibin or activin. 
7.4. General conclusion 
The data presented in this thesis demonstrate that adult-prostate derived stromal cells 
cultured from neoplastic lesions, produce a unique factor, tentatively called "prostate-derived 
Epithelium Inhibiting Factor": p-EIF. On the basis of its spectrum of biological activity as well 
as its physicochemical and immunoreactive properties, p-EIF can be discriminated from 
previously described growth inhibitors, including the TGF-B-related proteins inhibin and 
activin4~, and from interferon-fi l2 . It would be very interesting to investigate whether this 
unique factor is the major 'brake' on the prostate, controlling epithelial cell proliferation and 
thus prostatic size. The organ-specific production and the lack of inhibition on the non-
prostatic epithelial cell lines tested, suggest future organ-specific therapeutic potency. 
7.5. Discussion 
In this thesis the hypothesis of a negative control of prostatic epithelial cell 
proliferation by its stroma was investigated. The aforementioned idea was partly based on the 
observation that (normal) epithelial cells without stroma (Le., ill vitro) are able to proliferate in 
the absence of androgens, while androgen withdrawal in the intact organ or organ explant 
125 
Chapter 7 
culture leads to a massive reduction in epithelial cell number. One has to realize, however, 
that theoretically there are more options leading to this status. For instance, a cessation of 
androgen dependent secretion of stromally-derived epithelial growth stimulating factors in the 
intact organ may induce a similar cascade of involutional events. Cultures of normal prostatic 
murine- and human epithelial cells are not stimulated in their growth by androgens; the in vitro 
proliferation could then be caused by growth factors present in the culture medium that ill vivo 
would not be able to reach the epithelial compartment as will be discussed later. However, the 
discovery of epithelial cell inhibiting activity in stromal cell conditioned medium as described 
in this thesis, is favoring the first-mentioned hypothesis, 
A number of investigators has studied the stromal-epithelial interactions in the prostate 
in vitro, but their reports mainly focused on the mitogenic influence of the stroma45-49, 
supporting the second idea described above. No further reports from other groups have been 
published on stromally derived epithelial cell growth inhibitors in the adult prostate. 
Remarkably, all studies demonstrating stromal stimulation of prostatic epithelial cell growth 
were performed under serum-free conditions. Kirk, however, showed an inhibition of PC-3 
cell growth by lung fibroblasts, using a semm-dependent soft agar assay". Rowley rep0l1ed 
growth inhibition of a bladder carcinoma cell line by medium conditioned by urogenital sinus 
explants in the presence of 10% FCS 19 , Later on, it was shown that antiproliferative activity 
was produced by a fibroblastoid cell slrain probably derived from urogenital sinus 
mesenchyme51 • The presence of the 'Urogenital sinus derived Growth Inhibitory Factor' 
(UGIF) was tested in a semm-containing assay. Using physicochemical, biological, and 
immunological methods, UGIF was demonstrated to differ from known growth inhibiting 
factors including TGF-fi. Using the same bioassay, however, no activity could be found in 
chemically defined medium that was conditioned in exactly the same manner. Only the addition 
of steroid hormone caused the fibroblastoid cells to produce inhibiting activity that was 
ultimately identified as being caused by activated TGF-fi and not by UGIF". During the past 
decade, much effort has been put into the development of systems for senull-free culture of 
prostatic celis, Indeed, a semm-free environment is ideal for testing of regulatory peptides as 
well as for their identification, However, as a consequence of this simplification, certain 
infonnation about other growth regulating pathways may be lost as suggested by the results 
presented here and the findings reported by Kirk" and Rowley". These considerations bring to 
light a cmeial dilemma in oncological research, "Reduction gains precision about parts but at 
each step loses information about the larger organization it leaves behind n53. The glandular 
cells in the prostate receive nutrients, growth-modulating peptides, trophic nerve factors, and 
(steroid) hormones that have traversed the endothelial cells, stromal celis, extracellular matrix, 
and the acinar basement membrane. Consequently, the stromal compartment has ample 
126 
Summary and concluding remarks 
opportunity to modify epithelial cell microenvironment. It is conceivable that (perhaps 
unknown) serum-derived factors may very well participate in this, for instance by modifying 
stromal secretions, as was shown for androgen-induced epithelial cell proliferation in the rat 
prostates. Thus, tests perfOlTIled in the presence of serum or other undefined supplements, such 
as bovine pituitaty extract, will provide us with useful information about physiological and 
pathophysiological processes, and are essential to basic oncological research. However, these 
supplements will eventually hamper identification and isolation of the substance(s) of interest. 
So far, transforming growth factor-fi is the only well-known epithelial cell growth 
inhibitor that has been identified in the prostate13,35, and the secretion of TGF-fi by fibroblasts 
from other organs is also well documented lJ . Although p-EIF shares some similarities with 
type fi transforming growth factor (TGF-fi)-like inhibitors, evidence has been presented that the 
factor is not identical to TGF-B or to the TGF-fi-like factors activin and inhibin. It is 
concluded that prostate stroma-derived factor Illay be a novel growth inhibitor different from 
any of the currently described inhibiting factors. 
7,6, Future research 
A next step in the study of this factor would be a further biological characterization; it 
would be advisable to test its activity on a larger number of nonprostatic epithelial cell types to 
make sure that, besides the production, also the action is prostate specific. If so, this would be 
a great stimulus to prostate research, and might give rise to new developments in the selective 
treatment of prostatic neoplasia. The effect of p-EIF on primary cultures of prostatic 
epithelium from BPH or PC, for instance, should be investigated thoroughly as well as its 
effect on the stromal cells themselves in order to find out whether it is autostimulatOlY or 
inhibitory. The result may provide more information on its role in normal physiology and its 
possible involvement in the development of neoplasia. Although it may end up rather time 
consuming, efforts should be put into the purification of the inhibitor. As an example, the 
purification of inhibin should be kept in mind; after the introduction of the concept of inhibin, 
more than half a century passed before significant progress in the purification of gonadal 
inhibin was reported. Among other causes, this was thought to be due to the aberrant behavior 
of the molecule when conventional techniques were usedS-4. In general, the isolation of 
substances that are inhibitOlY in bio-assays is more difficult than purifying agents with a 
positive biological response, for every time the target cells show a reduced proliferation rate it 
has to be verified that it is really caused by the substance of interest and not the result of, for 
instance, cell toxic contaminants in the solution, a changed osmolarity, or a (very) high protein 
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content in the sample. 
For the time being, however, the presence of relatively large amounts of serum in the 
conditioned medium appears as an insunnountable problem. Purification at this stage can be 
considered as 'looking for a needle in the haystack', and should be postponed until the 
production of p-EIF has been realized under more appropriate conditions. Preliminaty data 
suggest that serum-derived factors are required for optimal production and/or secretion. 
Preliminary results however, failed to demonstrate significant effects of steroids (testosterone, 
dihydrotestosterone, or estradiol) in this respect. Further knowledge of the factors influencing 
its production may eventually facilitate purification and characterization. Antibodies raised 
against the purified factor would provide us with an excellent tool for snldying its role in 
normal physiology and its possible involvement in the development of neoplasia. 
It should be noted that it is possible that, at the end, 110 physiological or 
pathophysiological role for this substance can be defined. One might assume that the velY 
artificial circumstances like in vitro culture may lead to expression of previously 'hidden' 
genes resulting in the production and secretion of factors not seen ill vivo. Like the altered 
intermediate sized filament expression after ill vitro culture reported in this thesis (chapter3), it 
is conceivable that the production of inhibitory substances might be a similar unphysiological 
response to the unphysiological conditions. But even in that case it deserves our full attention 
because any agent that is capable of inhibiting prostatic epithelial (cancer) cells should be 
considered as a future treatment option in urological oncology. 
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Dutch summary 
De prostaat maakt deel uit van de mannelijke geslachtsorganen. De klier produceert een 
belangrijk deel van het semen en is gelegen rond de urinebuis aan de basis van de urineblaas in 
het kleine bekken. Een vergroting van het orgaan kan aanleiding geven tot klachten en kan 
bemsten op een goedaardige vergroting, ook weI BPR genoemd, of op prostaatkanker. Een 
wezenlijk verschil tussen beide vormen van overmatige groei is dat de kwaadaardige afwijking 
kan metastaseren (,uitzaaien') naar andere organen en op deze wijze aanleiding kan geven tot 
de dood van de patient. Na longkanker is het de belangrijkste oorzaak van kankersterfte in de 
Westerse wereld: per jaar worden in Nederland mim 4.000 nieuwe gevallen ontdekt terwijl 
jaarlijks mim 2.000 patienten aan de ziekte bezwijken. Als behandeling van het 
prostaatcarcinoom in een vroeg stadium (niet gemetastaseerd) kan operatie of radiotherapie 
(bestraling) toegepast worden. Een niet onaanzienlijk deel van de patienten wordt 
gediagnostiseerd op een moment dat er reeds metastasen aanwezig zijn, Het merendeel van hen 
reageert aanvankelijk goed op 'hormonale behandeling' hetgeen d.m. v. een medische of 
chilUrgische castratie wordt uitgevoerd, Na verloop van tijd wordt het prostaatcarcinoom 
echter ongevoelig Vaal' deze behandeling en zet het proces van tumorgroei zich voort, waarna 
tot op heden nog slechts palliatieve (symptoom-bestrijdende) ondersteuning rest. De oorzaken 
die aan de goedaardige en maligne nieuwvorming ten grondslag liggen, alsmede de 
mechanismen die progressie tot hOlIDoon-onafhankelijkheid van prostaatkanker bewerkstelligen 
zijn vooralsnog onopgehelderd. Men velIDoedt dat vele factoren een rol spelen bij het ontstaan 
hiervan, waaronder erfelijke aanleg, hormonale invloeden en de voeding, Met het werk 
beschreven in dit proefschrift werd getracht een bijdrage te leveren aan het in kaart brengen 
van de factoren welke de groei van prostaatcellen kunnen be'invloeden, 
De embryonale ontwikkeling en de (latere) groei en functie van de prostaat zijn 
afbankelijk van de aanwezigheid van mannelijke hormonen (androgenen). In hoofdsllIk 2 wordt 
een literatuuroverzicht gegeven van een aantal belangrijke (dier)experimenten welke tot een 
verdieping van ons inzicht in de hormonale regulatie van de prostaat(groei) hebben geleid. De 
klier bestaat zoals de meeste klieren voor het grootste deel uit bindweefsel (stroma) en 
klierweefsel (glandulair, epitheliaal weefsel). Vit de genoemde experimenten is gebleken dat de 
regulering van de door mannelijke hormonen geinduceerde embryonale groei en ontwikkeling 
verloopt via het stroma; indien er geen hormoonreceptor aanwezig is in het bindweefsel zal 
geen prostaat aangelegd worden, Door nader onderzoek werden eveneens aanwijzingen 
verkregen die erop duiden dat ook in de volwassen prostaat belangrijke androgene 
(groei)effecten via het stroma kan verlopen. Anderszins kan men vermoeden dat omgekeerd 
ook de afname (involutie) van de klier(grootte), bijvoorbeeld t.g.v. hormoononttrekking, 
evenzo door het stroma gereguleerd kan worden. Ook het feit dat de klier onder invloed van 
hormonen (in de puberteit) uitgroeit tot een bepaalde maximum grootte en dat er ondanks de 
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blijvende aanwezigheid van androgenen geen verdere (overmatige) volumetoename resultee11, 
zou middels een negatieve controle (renunende invloed) vanuit het stroma verklaard kUlmen 
worden. De negatieve controle zou kunnen bestaan uit een afname van positieve groei-effeeten 
danwel als een toename van groei-remmende faetoren. De meeste experimenten ill vitro 
(m,b, v, celkweken) laten een groei-stimulerende invloed zien van gekweekte bindweefselcellen 
op epitheelceUen van de prostaat. 
In dit proefschrift worden experimenten beschreven welke werden uitgevoerd met 
kweken van humane stromale cellen van de prostaat en de bekende in vitro tumorcelIijnen van 
de menselijke prostaat: PC-3 en LNCaP, alsmede de Dunning (rat)prostaat-tumorcellijnen 
MATLyLu en AT-2, L De stromale cellen werden gekweekt van ziek prostaat weefsel 
afkomstig van patienten met BPH en van patienten met een prostaatcarcinoom. Een goede 
karakterisering van deze kweken van humane stromale cellen was nog niet in de literatuur 
gemeld, In hoof tis/ilk 3 wordt de immunocytochemische karakterisering besproken, Hiertoe 
werden antilichamen gebroikt welke gericht zijn tegen specifieke eiwitkomponenten van het 
celskelet (,intermediate sized filament proteins'): keratine, desmine en vimentine. 
Aanwezigheid van deze eiwitten is kal'akteristiek voor cellen afkomstig van respectievelijk 
epitheel, spier- en bindweefseL Tevens we I'd gekleurd met antistoffen tegen actine afkomstig 
van gladde spiercellen, Door het tellen van het aantal aangekleurde cellen in een bepaalde 
kweek (van een bepaalde patient) werd duidelijk dat d,m,v, de toegepaste, relatief eenvoudige, 
methode van 'explant-culture' reeds in de eerste passage ('kweekronde') een vrij zuivere 
kweek van stromale cellen kon worden verkregen: < 5 % contaminatie met epitheliaJe cellen. 
In de volgende (sub)cultures nam dit percentage snel nog verder af. Opmerkelijk was de 
bevinding dat kweken afkomstig van de maligne afwijking beduidend meer cellen bevatten met 
eigenschappen van gladde spiercellen dan de BPH cultures, Dergelijke cellen, ook wei 
aangeduid als myofibroblasten, werden oak gemeld aanwezig te zijn in andere tumoren; ze 
zouden verantwoordelijk zijn voor de desmoplastische reactie zoals die beschreven is 
bijvoorbeeld in samenhang met het mammacarcinoom (borstkanker), Ondanks het verschi! in 
fenotype ('uiterlijk') van de kweken van BPH en prostaatcarcinoom werd bij de in dit 
proefschrift beschreven proeven geen duidelijk verschi! gevonden in de uitkomsten van de 
experimenten, Dit zou (mede) verklaard kunnen worden uit het feit dat het 
(inununocytochemische) verschi! tussen beide celkweektypen afnam tijdens het doorkweken (na 
enkele passages) in combinatie met feit dat voor het verkrijgen van voldoende cellen het 
opkweken gedurende minimaal drie passages onvermijdelijk was, 
Hooftls/llk 4 beschrijft het effect dat stromale cellen hebben op de groei van de 
genoemde humane epitheliale cellijnen van de prostaat. Hiertoe werden de epitheelceUen in een 
tweelagig 'soft-agar' testsysteem samengebracht met de bindweefselcellen, In dit systeem zijn 
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de celtypen ruimtelijk, doch niet (bio)chemisch, van elkaar gescheiden. Bij deze tests die 
werden uitgevoerd in de aanwezigheid van serum (een rijk voedingsmedium) bleek de graei 
van het epitheel geremd te worden, de mate van remming was (binnen bepaalde grenzen) 
evenredig met het aantal meegekweekte stromacellen. Nadere analyse suggereerde de 
aanwezigheid van een graeiremmende stof in het kweekmedium (geconditioned medium: CM) 
van de stromacellen. 
Door het gebruik van een meer handzame test (MTT -test), waarbij de epitheelcellen 
worden gekweekt in multiwell platen en de hoeveelheid cellen aan het einde van een groeitest 
(semi-)automatisch kan worden bepaald, werd het mogelijk meerdere monsters tegelijkertijd te 
testen. In !wofdstuk 5 wordt aangetoond dat naast de 'non-anchorage dependent growth' (groei 
in agar) van de epitheelcellen ook de 'anchorage dependent growth' (groei op de bodem van 
weefselkweekmateriaal) wordt geremd door eM van stromacellen. De proliferatie van zowel 
de hormoonafhankelijke LNCaP cellijn als de hormoonongevoelige PC-3 cellijn neemt daarbij 
af. Het effect bleek reversibel, en werd uitsluitend gevonden in het CM van stromacellen van 
de prostaat: bindweefselcelkweken afkomstig van huid, preputium (voorhuid), uterus 
(baarmoeder), nier en Wilms' tumorweefsel Heten geen significante remming zien in de tests. 
Het effect bleek niet (dier)soortspecifiek daar ook de Dunning prostaattumor-cellijnen 
MATLyLu en AT-2.1, afkomstig van de rat, werden geremd in hun groei. De aanwezigheid 
van een specifieke groeiremmende factor (inhibitor) werd mede ingegeven door het feit dat het 
inhibitoire effect kon worden geconcentreerd door het uit het (serumhoudende) 
geconditioneerde medium neer te slaan (precipiteren); op deze wijze kon, door de factor 
opnieuw in een weinig medium op te lossen, een zeer potent concentraat bemachtigd worden 
(tot 90% groeiremming in de MTT-test). Bij deze procedure gelukte het tevens om ca 75% van 
de overtollige (serum)eiwitten kwijt te raken. 
De verklaring VOOI het gegeven dat de meeste artikelen over dit onderwerp een 
stromale stimulering van het epitheel beschrijven Iijkt te IllOeten worden gezocht in het al of 
niet aanwezig zijn van serum bij de proeven hetgeen in de laatste hoofdstukken wordt 
bediscussieerd. Samengevat lijkt het dat de inhibitor uitsluitend wordt geproduceerd in 
aanwezigheid van serum. Men moet zich daarbij oak realiseren dat ill vivo met name de 
bindweefselcellen in nauw contact staan met het bloed en Iymfevocht, en dat bij het ontberen 
hiervan een mindel' fysiologische omgeving resulteert. Anderzijds kan de aanwezigheid van 
serum het identificeren, en met name het isoleren van groei~modulerende factoren ernstig 
hinderen. In dit verband geldt het adagium: "Reduction gains precision about parts but at each 
step loses information about the larger organization it leaves behind" (Smithers, referentie 122, 
hoofdstuk 2). 
Vit hoofds/llk 6 blijkt dat de in dit werk gevonden remmende factor zich onderscheidt 
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van andere, reeds bekende inhibitoren. Fysico-chemisch onderzoek toonde dat de factor 
gevoelig is voor reducerende stoffen en proteolytische enzymen hetgeen de aanwezigheid van 
eiwitstructuren met daarin disulfidebruggen demonstreell, die nodig zijn voor biologische 
activiteit. Daarnaast leek er sprake van zuur- en hitte-instabiliteit. Met name de laatste twee 
eigenschappen differentieren de factor van de veel beschreven Transforming Growth Factor B 
(TGF-B) en zijn sUbtypen. Ondanks het feit dat commercieel verkrijgbaar (runder)serum ook 
latent TGFB bevat, kon middels biologische tests op de voor TGFB zeer gevoelige CCL-64 
cellijn alsmede inmmnologische proeven met neutraliserende antistoffen het onderscheid 
aannemelijk worden gemaakt. Vooralsnog werd de factor vanaf dit moment aangeduid met p-
ElF: prostate-derived Epithelium Inhibiting Factor. 
Geconcludeerd wordt dat het hier wellicht handelt om een nieuwe groei-modulerende 
factor die mede gezien de prostaat-specifieke produktie uniek genoemd mag worden. Verder 
onderzoek lijkt ten zeerste gerechtvaardigd. 
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aFGF 
AR 
bFGF 
BPH 
BSA 
CM 
DAB 
DHT 
DMEM 
DMSO 
DNA 
DTT 
ECM 
EDGF 
EDIF 
EDTA 
EGF 
ER 
EVE 
EVS 
FCS 
Gy 
IFN 
KGF 
LHRH 
MEM 
MTT 
NGF 
NP 
PA 
PBS 
PC 
PE 
p-EIF 
RNA 
SD 
SDGF 
SM 
STI 
Tfm 
TGF-B 
UGIF 
VE 
VS 
Abbreviations 
acidic fibroblast growth factor 
androgen receptor 
basic fibroblast growth factor 
benign prostatic hyperplasia 
bovine serum albumin 
Conditioned medium 
3,3' -diaminobenzidine 
dihydrotestosterone 
Dulbecco's modified Eagle medium 
dimethylsulfoxide 
deoxyribonucleic acid 
dithiothreitol 
extracellular matrix 
epithelially derived growth factor 
epithelially derived inhibiting factor 
ethylene-diamino-tetra-acetate 
epidelmal growth factor 
estrogen receptors 
estrogen treated vaginal epithelium 
estrogen treated vaginal stroma 
fetal calf semm 
gray 
interferon 
keratinocyte growth factor 
luteinizing honnone-releasing hOlmone 
minimum essential medium 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
nerve growth factor 
nannal prostatic tissue 
prostate adenoma ~ benign prostatic hyperplasia 
phosphate buffered saline 
prostate carcinoma 
plating efficiency 
prostate-derived epithelium inhibiting factor 
ribonucleic acid 
standard deviation 
stromally derived growth factor 
smooth muscle 
soybean trypsin inhibitor 
testicular feminization 
transforming growth factor-beta 
urogenital sinus-derived inhibitory factor 
vaginal epithelium 
vaginal stroma 
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